[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3891
1. Tjalsma H, Pluk W, van den Heuvel LP, Peters WH, Roelofs R, Swinkels DW: Proteomic inventory of "anchorless" proteins on the colon adenocarcinoma cell surface. Biochim Biophys Acta; 2006 Oct;1764(10):1607-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic inventory of "anchorless" proteins on the colon adenocarcinoma cell surface.
  • Importantly, these proteins may comprise attractive therapeutic targets and novel disease markers for colon cancer.
  • To perform a proteomics-based inventory of these so-called "anchorless" surface proteins, intact colon adenocarcinoma SW480 cells were labeled with membrane-impermeable biotin after which only soluble biotinylated proteins were isolated and identified by nanoLC-MS/MS.
  • This underscores the importance of post-proteomic verification of proteomics-based inventories on surface-exposed proteins, which eventually should reveal to which extent non-classical export and retention mechanisms contribute to the sorting of "anchorless" proteins to the surface of colon tumor cells.
  • [MeSH-major] Adenocarcinoma / chemistry. Colonic Neoplasms / chemistry. Membrane Proteins / analysis. Neoplasm Proteins / analysis. Proteome / analysis. Proteomics / methods

  • Hazardous Substances Data Bank. BIOTIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030026.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Proteome; 6SO6U10H04 / Biotin
  •  go-up   go-down


2. Brozek W, Bises G, Girsch T, Cross HS, Kaiser HE, Peterlik M: Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. Eur J Cancer; 2005 Oct;41(15):2347-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression.
  • Interleukin (IL)-6 mRNA expression in general is low in normal, adenomatous and cancerous human colon mucosa, except in rather undifferentiated lesions, in which IL-6 is overexpressed.
  • Likewise, in five (sub)clones of primary culture COGA-1 and COGA-13 human colon carcinoma cells, and in three established cell lines (Caco-2/AQ, Caco-2/15 and HT-29), efficient translation of IL-6 mRNA into protein was observed only in the least differentiated COGA-13 cells.
  • Our data imply that IL-6, when released from rather undifferentiated carcinoma cells, particularly in response to IL-1beta, can advance tumour progression through paracrine growth stimulation of normal or highly differentiated colon tumour cells with intact STAT-3-mediated IL-6 signalling.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Cytokines / pharmacology. Interleukin-6 / metabolism. Mitogens / metabolism
  • [MeSH-minor] Cell Division. Cell Transformation, Neoplastic. Colon / metabolism. Disease Progression. Enzyme-Linked Immunosorbent Assay. Humans. Immunohistochemistry. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176872.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Mitogens; 0 / RNA, Messenger
  •  go-up   go-down


3. Hardouin J, Lasserre JP, Canelle L, Duchateau M, Vlieghe C, Choquet-Kastylevsky G, Joubert-Caron R, Caron M: Usefulness of autoantigens depletion to detect autoantibody signatures by multiple affinity protein profiling. J Sep Sci; 2007 Feb;30(3):352-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with cancer produce specific autoantibodies against protein antigens present in limited amount among a large background of immunoglobulins (Igs), nonrelevant as biomarkers, including natural antibodies.
  • Application of this depletion step to colon cancer cell proteins is specifically described along with the identification of the natural autoantigens, as well as the coupling of this depletion step with the next steps.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / immunology. Aged. Amino Acid Sequence. Antibodies, Neoplasm / isolation & purification. Antigens, Neoplasm / genetics. Antigens, Neoplasm / isolation & purification. Caco-2 Cells. Colonic Neoplasms / genetics. Colonic Neoplasms / immunology. Humans. Middle Aged. Molecular Sequence Data. Tandem Mass Spectrometry

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17396593.001).
  • [ISSN] 1615-9306
  • [Journal-full-title] Journal of separation science
  • [ISO-abbreviation] J Sep Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Autoantigens
  •  go-up   go-down


Advertisement
4. Borrelli F, Capasso R, Aviello G, Di Carlo G, Izzo AA, Mascolo N, Capasso F: Senna and the formation of aberrant crypt foci and tumors in rats treated with azoxymethane. Phytomedicine; 2005 Jun;12(6-7):501-5; discussion 505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic use of anthraquinone laxatives has been blamed for the induction of habituation and the development of colonic cancer, but there are no definitive studies which have demonstrated this.
  • These results suggest that a chronic SE use does not predispose to colon cancer.
  • By contrast, SE might exert an anti-tumoral activity on rat colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma / prevention & control. Anticarcinogenic Agents / pharmacology. Colonic Neoplasms / prevention & control. Phytotherapy. Senna Extract / pharmacology. Senna Plant

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008128.001).
  • [ISSN] 0944-7113
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cathartics; 8013-11-4 / Senna Extract; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


6. Bataille F, Rogler G, Modes K, Poser I, Schuierer M, Dietmaier W, Ruemmele P, Mühlbauer M, Wallner S, Hellerbrand C, Bosserhoff AK: Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin. Lab Invest; 2005 Jan;85(1):124-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin.
  • The MTAP gene is localized on the human chromosomal region 9p21, a region often deleted in cancer.
  • The aim of this study was to analyse the role of MTAP in colon carcinoma and normal colon epithelium and the regulation of gene expression.
  • To examine MTAP RNA and protein expression, we screened six colon carcinoma cell lines and human primary colon epithelial cells by RT-PCR and immunoblotting.
  • MTAP expression was confirmed in vivo by immunohistochemical staining of normal colon tissue compared to adenoma and colon carcinoma.
  • Interestingly, we found strong MTAP mRNA and protein expression by colon carcinoma cell lines but no expression by colonic epithelial cells.
  • In addition, the recently postulated association between MTAP activity and interferon (IFN) sensitivity was confirmed in colon epithelial cells showing only little response to IFN-gamma, in contrast to the carcinoma cell lines.
  • In summary, these data indicate for the first time that MTAP is not expressed in normal human colonic epithelium but is strongly upregulated in colon carcinoma.
  • This finding may be of clinical significance concerning the homeostasis of normal colon epithelium and potential treatment of colon carcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Colonic Neoplasms / enzymology. Cytoskeletal Proteins / metabolism. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Neoplastic. Nuclear Proteins / metabolism. Purine-Nucleoside Phosphorylase / genetics. Trans-Activators / metabolism. Transcription Factors / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492751.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / HNF1A protein, human; 0 / Hepatocyte Nuclear Factor 1-alpha; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / Transcription Factors; 0 / beta Catenin; 126548-29-6 / Hepatocyte Nuclear Factor 1; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 2.4.2.28 / 5'-methylthioadenosine phosphorylase
  •  go-up   go-down


7. Osuagwu CC, Okafor OC, Ezeome ER, Uche CE, Ememonu C, Kesieme E: Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male. Rare Tumors; 2010;2(4):e66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male.
  • This patient presented with partial large bowel obstruction and the pathological analysis revealed 4 invasive adenocarcinomas, 3 in the colon and 1 in the jejunum (Dukes stage D).
  • The challenges of managing a hereditary cancer syndrome in a resource poor country are highlighted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Nov 14;14(42):6531-5 [19030207.001]
  • [Cites] East Afr Med J. 1995 Apr;72(4):267-8 [7621765.001]
  • [Cites] West Afr J Med. 2001 Oct-Dec;20(4):251-5 [11885882.001]
  • [Cites] Cent Afr J Med. 1992 Jan;38(1):44-8 [1321689.001]
  • [Cites] Niger J Med. 2005 Apr-Jun;14(2):161-6 [16083239.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cent Afr J Med. 1994 Jan;40(1):8-13 [8082150.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] JOP. 2008;9(1):9-18 [18182737.001]
  • [Cites] Neth J Med. 1989 Jun;34(5-6):317-21 [2549435.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1982-7 [8247073.001]
  • [Cites] Dis Colon Rectum. 1996 May;39(5):536-40 [8620804.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • (PMID = 21234258.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019601
  • [Keywords] NOTNLM ; adenocarcinoma. / colon / familial adenomatous polyposis / jejunum
  •  go-up   go-down


8. Yin P, Qiu XF, Liu ZC: [Expression of inductive nitric oxide synthase and vascular endothelial growth factor in colonic carcinoma, and their effects on tumor angiogenesis]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Nov;8(6):513-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of inductive nitric oxide synthase and vascular endothelial growth factor in colonic carcinoma, and their effects on tumor angiogenesis].
  • OBJECTIVE: To investigate the expression of inductive nitric oxide synthase (iNOS) and vascular endothelial growth factor (VEGF), and their relations with clinicopathological parameters in colonic carcinoma.
  • METHOD: Immunohistochemistry (streptomycin avidin-biotin peroxidase complex, SP) was used to detect the expression of iNOS, VEGF, collagen IV, FVIII Ag in colonic adenocarcinoma, and micro vessel density (MVD) was counted.
  • RESULTS: The positive rates of iNOS and VEGF in colonic carcinoma were 76% and 80% respectively.
  • The expression of VEGF was correlated with tumor invasion, differentiation and lymph no de metastasis, but not with patients age,sex and histologic type.
  • CONCLUSION: The expression of iNOS and VEGF may play a role in the angiogenesis, metastasis and invasion of colonic carcinoma.
  • [MeSH-major] Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Nitric Oxide Synthase Type II / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16299654.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


9. Popowich DA, Halverson AL: Medical oncology: Multimodality therapy in unresectable colorectal cancer. Nat Rev Clin Oncol; 2009 Jun;6(6):305-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical oncology: Multimodality therapy in unresectable colorectal cancer.
  • Mathis et al. aimed to determine the effect of multimodality therapy on recurrence and survival in patients with locally advanced colorectal cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Colorectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Surg. 2008 Oct;248(4):592-8 [18936572.001]
  • (PMID = 19483732.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Son HJ, Kim JS: Therapeutic efficacy of DNA-loaded PLGA microspheres in tumor-bearing mice. Arch Pharm Res; 2007 Aug;30(8):1047-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo gene therapy was attempted using poly-(D,L-lactic-co-glycolic acid) microspheres containing the interleukin-12 gene (p2CMVmlL12) in colon adenocarcinoma (CT-26)-bearing Balb/ c mice.
  • [MeSH-major] Adenocarcinoma / therapy. DNA / administration & dosage. Drug Carriers / chemistry. Gene Transfer Techniques. Genetic Therapy. Interleukin-12 / genetics. Lactic Acid / chemistry. Polyglycolic Acid / chemistry. Polymers / chemistry

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879760.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Carriers; 0 / Polymers; 0 / polylactic acid-polyglycolic acid copolymer; 187348-17-0 / Interleukin-12; 26009-03-0 / Polyglycolic Acid; 33X04XA5AT / Lactic Acid; 9007-49-2 / DNA; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Agboola AO, Adekanmbi FA, Musa AA, Sotimehin AS, Deji-Agboola AM, Shonubi AM, Oyebadejo TY, Banjo AA: Pattern of childhood malignant tumours in a teaching hospital in south-western Nigeria. Med J Aust; 2009 Jan 5;190(1):12-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One case each of medullary thyroid carcinoma, adenocarcinoma of the rectum, invasive mucinous carcinoma of the colon were also identified.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19120001.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


12. Cho YK, Kim HC, Kim SH, Park JH, Yun HR, Cho YB, Yun SH, Lee WY, Chun HK: Location-related differences in sporadic microsatellite unstable colorectal cancer. Dig Liver Dis; 2010 Sep;42(9):611-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Location-related differences in sporadic microsatellite unstable colorectal cancer.
  • AIMS: Site-specific heterogeneity of sporadic microsatellite unstable colorectal cancer (CRC) based on location was elucidated.
  • RESULTS: Among the 164 MSI-H CRC, 105 (64.0%) were located in the proximal colon and 59 (36.0%) were located in the distal colon.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Microsatellite Instability. Nuclear Proteins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20227930.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


13. Lash RH, Genta RM, Schuler CM: Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol; 2010 Aug;63(8):681-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Sessile serrated adenomas (SSAs) are recognised as precursors to microsatellite unstable adenocarcinomas.
  • There were 1816 (85%) patients without dysplasia (SSA-), 257 (12%) with low-grade dysplasia (SSA-LD), 45 (2%) with high-grade dysplasia (SSA-HD) and 21 (1%) with adenocarcinoma (SSA-CA).
  • Women comprised 53% of the SSA- group (968/1816), 57% of the SSA-LD group (147/257), 69% of the SSA-HD group (31/45) and 76% of the SSA-CA group (16/21), being more likely to have high-grade dysplasia (OR 1.94, 95% CI 1.03 to 3.67) and adenocarcinoma (OR 2.80, 95% CI 1.02 to 7.68).
  • CONCLUSIONS: 1.7% of patients with mucosal polyps had SSAs (with and without dysplasia), more commonly in women and primarily in the right colon.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy. Colonoscopy. Disease Progression. Female. Humans. Intestinal Polyps / epidemiology. Intestinal Polyps / pathology. Male. Middle Aged. Prevalence. United States / epidemiology. Young Adult


14. Sperti C, Pasquali C, Fiore V, Bissoli S, Chierichetti F, Liessi G, Pedrazzoli S: Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms. Am J Surg; 2006 Jun;191(6):743-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: 18-Fluorodeoxyglucose positron emission tomography (18-FDG PET) has been investigated for the diagnosis and staging of gastrointestinal malignancies including pancreatic adenocarcinoma.
  • Follow-up evaluation including CT scan and PET was performed in 12 patients: PET showed recurrent disease not seen by CT in 4 patients, confirmed CT findings in 6 patients, and showed an unsuspected primary lung cancer in 1 patient and colon cancer in another patient.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720142.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


15. Hohenberger W, Merkel S, Weber K: [Lymphadenectomy with tumors of the lower gastrointestinal tract]. Chirurg; 2007 Mar;78(3):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Lymphadenektomie bei Tumoren des unteren Gastrointestinaltraktes.
  • For advanced adenocarcinomas, which are the most frequent tumours of the lower GI tract, the concept of radical lymphnode dissection is well accepted.
  • The quality of lymphadenectomy for these malignancies has a strong effect on cancer-related survival.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Anus Neoplasms / pathology. Anus Neoplasms / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Humans. Intestines / pathology. Intestines / surgery. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Lymphoma / pathology. Lymphoma / surgery. Neoplasm Staging. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Jpn J Surg. 1983 Nov;13(6):557-73 [6672390.001]
  • [Cites] Fortschr Med. 1986 Feb 27;104(8):167-70 [3957212.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Chirurg. 2003 Oct;74(10):897-904 [14605731.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Langenbecks Arch Surg. 1998 Dec;383(6):402-8 [9921939.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Br J Surg. 2003 Dec;90(12):1580-5 [14648739.001]
  • [Cites] J Am Coll Surg. 1997 Jun;184(6):584-8 [9179114.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] World J Surg. 1996 Feb;20(2):132-41 [8661808.001]
  • [Cites] Chirurg. 2004 Aug;75(8):761-6 [15232693.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Am J Surg. 2006 Mar;191(3):305-10 [16490536.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Z Gastroenterol. 2004 Sep;42(9):1067-72 [15455287.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Chirurg. 2007 Aug;78(8):739-47 [17569018.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] J R Soc Med. 1988 Sep;81(9):503-8 [3184105.001]
  • [Cites] Surg Endosc. 1989;3(2):96-9 [2672395.001]
  • [Cites] J Am Coll Surg. 1997 May;184(5):475-80 [9145067.001]
  • [Cites] Digestion. 1994;55 Suppl 3:11-23 [7698533.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Scand J Surg. 2003;92(1):45-52 [12705550.001]
  • [Cites] Chirurg. 2006 Jan;77(1):33-40 [16372188.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2740-6 [12860953.001]
  • (PMID = 17333036.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Nagatomo A, Abe N, Takeuchi H, Yanagida O, Masaki T, Mori T, Sugiyama M, Ohkura Y, Fujioka Y, Atomi Y: Microscopic cancer cell spread in gastric cancer: whole-section analysis of mesogastrium. Langenbecks Arch Surg; 2009 Jul;394(4):655-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic cancer cell spread in gastric cancer: whole-section analysis of mesogastrium.
  • PURPOSE: Cancer cells are often found in adipose connective tissue separate from the primary lesion and outside lymph nodes on routine pathologic examination of resected gastric cancer specimens.
  • To identify the anatomical relationship between such cancer cell spread and lymph nodes, we investigated the microscopic cancer cell spread in the mesogastrium (CSM) by the whole-section analysis of the mesogastrium.
  • METHOD: One thousand five hundred fifty-two sections of the mesogastrium obtained from 37 patients with gastric cancer were subjected.
  • CSM is defined as the existence of cancer cell spread in the mesogastrium separate from the primary lesion.
  • CSM was found in three of the 12 patients with advanced cancer, but not in 25 patients with early cancer.
  • CONCLUSIONS: CSM may occur in the mesogastrium separate from metastatic lymph nodes; therefore, we should pay particular attention to the potential existence of CSM in surgery for gastric cancer.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Papillary / pathology. Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2755-7 [7872713.001]
  • [Cites] Am J Surg. 2005 Sep;190(3):496-503 [16105543.001]
  • [Cites] J Surg Oncol. 2000 Nov;75(3):165-71 [11088047.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1193-9 [16938525.001]
  • [Cites] Surg Today. 1997;27(7):617-22 [9306563.001]
  • [Cites] J Clin Pathol. 1994 Oct;47(10):920-3 [7962605.001]
  • [Cites] Br J Surg. 2006 Mar;93(3):369-73 [16392106.001]
  • [Cites] Pancreas. 2006 Jan;32(1):62-6 [16340746.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1255-7 [12218087.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):55-61 [9510311.001]
  • [Cites] Surgery. 2004 Mar;135(3):266-72 [14976476.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1258-62 [10506712.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2268-72 [9404704.001]
  • [Cites] J Surg Oncol. 1997 Jan;64(1):12-6 [9040794.001]
  • [Cites] Gastric Cancer. 2001;4(3):150-5 [11760081.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):452-6 [8422638.001]
  • [Cites] Am Surg. 2003 Jul;69(7):573-7 [12889619.001]
  • [Cites] Surgery. 2005 May;137(5):511-7 [15855922.001]
  • (PMID = 18931855.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Krakowczyk L, Strzelczyk JK, Adamek B, Zalewska-Ziob M, Arendt J, Półtorak S, Maciejewski B, Wiczkowski A: Methylation of the MGMT and p16 genes in sporadic colorectal carcinoma and corresponding normal colonic mucosa. Med Sci Monit; 2008 Oct;14(10):BR219-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of the MGMT and p16 genes in sporadic colorectal carcinoma and corresponding normal colonic mucosa.
  • BACKGROUND: Colorectal cancer, one of the most aggressive cancers, occurs with a high incidence in most countries.
  • Cancer development and progression is dictated by series of alterations in genes such as tumor suppressor genes, DNA repair genes, oncogenes and others.
  • In our study we analyzed methylation of CpG islands in the MGMT and p16 genes in sporadic colorectal cancers and normal corresponding colonic mucosa.
  • MATERIAL/METHODS: Fresh tissue samples were obtained from 68 patients (age of 23 to 81 years) with primary colorectal adenocarcinoma and corresponding normal tissues.
  • In corresponding normal colonic mucosa methylation of MGMT was detected in 20% and p16 in 18%.
  • The normal colon mucosa obtained from younger patients (age of <65 years) showed less methylation frequency as compared with the normal mucosa from the older ones (age of >65 years).
  • CONCLUSIONS: The older age and female gender are generally associated with higher methylation levels for most CpG islands in normal colonic mucosa.
  • These results indicate that MGMT and/or p16 aberrant methylation may play an important role in colorectal cancer.
  • [MeSH-major] Colon / anatomy & histology. Colorectal Neoplasms / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Genes, p16. Intestinal Mucosa / anatomy & histology. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18830187.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


18. Chartier NT, Oddou CI, Lainé MG, Ducarouge B, Marie CA, Block MR, Jacquier-Sarlin MR: Cyclin-dependent kinase 2/cyclin E complex is involved in p120 catenin (p120ctn)-dependent cell growth control: a new role for p120ctn in cancer. Cancer Res; 2007 Oct 15;67(20):9781-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin-dependent kinase 2/cyclin E complex is involved in p120 catenin (p120ctn)-dependent cell growth control: a new role for p120ctn in cancer.
  • Overexpression of the p120ctn isoform 3A in human colon adenocarcinoma cells (HT-29) results in cytoplasmic accumulation of the protein, as observed in many tumors.
  • Because these modifications are often observed in cancer, p120ctn may represent a new therapeutic target for future therapy.
  • [MeSH-major] Cell Adhesion Molecules / metabolism. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Cyclin E / metabolism. Cyclin-Dependent Kinase 2 / metabolism. Phosphoproteins / metabolism

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10938-45 [16322241.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1669-79 [8114703.001]
  • [Cites] J Cell Sci. 2006 Jan 1;119(Pt 1):31-46 [16339173.001]
  • [Cites] Cell. 2006 Feb 10;124(3):631-44 [16469707.001]
  • [Cites] World J Gastroenterol. 2006 Feb 28;12(8):1187-91 [16534869.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):606-9 [16582601.001]
  • [Cites] J Cell Biol. 1995 Jul;130(1):105-15 [7790366.001]
  • [Cites] EMBO J. 1996 Aug 15;15(16):4182-93 [8861947.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6623-33 [8943316.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Prog Cell Cycle Res. 1995;1:125-39 [9552358.001]
  • [Cites] Methods Cell Biol. 1999;61:13-34 [9891307.001]
  • [Cites] Science. 1999 Feb 5;283(5403):851-4 [9933170.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2817-22 [10077594.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3614-23 [10207085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7980-5 [10393933.001]
  • [Cites] Nature. 1999 Sep 16;401(6750):297-300 [10499591.001]
  • [Cites] Semin Cell Dev Biol. 2004 Dec;15(6):657-63 [15561585.001]
  • [Cites] Genes Cells. 2005 Jan;10(1):75-86 [15670215.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2776-86 [15838514.001]
  • [Cites] Cancer Lett. 2005 Dec 8;230(1):6-19 [16253756.001]
  • [Cites] Curr Opin Cell Biol. 2006 Oct;18(5):507-15 [16919436.001]
  • [Cites] J Cell Biol. 2006 Sep 25;174(7):1087-96 [16982802.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1027-39 [17129786.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1773(1):34-46 [17028013.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2020-8 [10580027.001]
  • [Cites] J Cell Biol. 2000 Jan 10;148(1):189-202 [10629228.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(2):231-46 [10728986.001]
  • [Cites] Cell. 2000 Sep 29;103(1):127-40 [11051553.001]
  • [Cites] Curr Opin Cell Biol. 2000 Dec;12(6):676-84 [11063931.001]
  • [Cites] Mol Cell Biol. 2001 May;21(9):3256-65 [11287628.001]
  • [Cites] Breast Cancer Res. 2001;3(5):289-93 [11597316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1978-83 [11830638.001]
  • [Cites] Cell Cycle. 2002 Jan;1(1):75-81 [12429912.001]
  • [Cites] Cell Cycle. 2003 Jul-Aug;2(4):316-24 [12851482.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S38-47 [14508079.001]
  • [Cites] J Cell Biol. 2003 Nov 10;163(3):547-57 [14610057.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):65-75 [14965268.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6588-94 [14660598.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9512-21 [14676216.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3272-83 [15077190.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):19592-9 [14985333.001]
  • [Cites] J Cell Sci. 2004 Jun 1;117(Pt 13):2675-86 [15138284.001]
  • [Cites] J Cell Biol. 2004 Jun 21;165(6):789-800 [15197178.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4800-9 [15256449.001]
  • [Cites] Oncogene. 2004 Oct 18;23(48):7947-56 [15489912.001]
  • [Cites] Cell. 1991 Jul 12;66(1):107-19 [2070412.001]
  • [Cites] Science. 1993 Mar 26;259(5103):1908-12 [8384376.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):956-64 [16294216.001]
  • (PMID = 17942908.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catenins; 0 / Cell Adhesion Molecules; 0 / Cyclin E; 0 / Phosphoproteins; 0 / Recombinant Fusion Proteins; 0 / delta catenin; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  • [Other-IDs] NLM/ HALMS263580; NLM/ PMC2695941
  •  go-up   go-down


19. Ahn EM, Bang MH, Song MC, Park MH, Kim HY, Kwon BM, Baek NI: Cytotoxic and ACAT-inhibitory sesquiterpene lactones from the root of Ixeris dentata forma albiflora. Arch Pharm Res; 2006 Nov;29(11):937-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds 1, 2 and 7 revealed relatively high cytotoxicities on human colon carcinoma cell and lung adenocarcinoma cell, while compounds 5 and 7 showed acyl-CoA: cholesterol acyltransferase (ACAT) inhibitory activity.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Animals. Cell Line, Tumor. Cell Survival. HT29 Cells. Humans. In Vitro Techniques. Lung Neoplasms / drug therapy. Magnetic Resonance Spectroscopy. Male. Microsomes, Liver / drug effects. Microsomes, Liver / enzymology. Microsomes, Liver / metabolism. Rats. Spectrophotometry, Infrared

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17146959.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Lactones; 0 / Sesquiterpenes; EC 2.3.1.26 / Sterol O-Acyltransferase
  •  go-up   go-down


20. Yang XW, Yang XD, Wang Y, Ma L, Zhang Y, Yang XG, Wang K: [Establishment of Caco-2 cell monolayer model and standard operation procedure for assessing intestinal absorption of chemical components of traditional Chinese medicine]. Zhong Xi Yi Jie He Xue Bao; 2007 Nov;5(6):634-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To establish Caco-2 (a human colon adenocarcinoma cell line) cell monolayer model and the standard operation procedure for studying and assessing intestinal absorption of chemical components of traditional Chinese medicine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997937.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Flavonoids
  •  go-up   go-down


21. Solon JG, Al-Azawi D, Hill A, Deasy J, McNamara DA: Colonoscopy and computerized tomography scan are not sufficient to localize right-sided colonic lesions accurately. Colorectal Dis; 2010 Oct;12(10 Online):e267-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonoscopy and computerized tomography scan are not sufficient to localize right-sided colonic lesions accurately.
  • AIM: Accurate preoperative localization of colonic lesions is critical especially in laparoscopic colectomy where tactile localization is absent particularly in screen-detected tumours.
  • RESULTS: Out of 101 patients, 73 (73%) were for adenoma or cancer, with a final diagnosis of adenocarcinoma in 59 (58%).
  • In the transverse colon, colonoscopy alone was only 37.5% accurate, increasing to 62.5% when information from the CT scan was added.
  • CONCLUSION: Preoperative localization of right-sided colon cancers using colonoscopy and CT scanning is unreliable in at least 29% of cases.
  • Inaccurate localization of transverse colon tumours risks inadequate lymphadenectomy with an adverse cancer outcome.
  • [MeSH-major] Cecum / pathology. Colon, Ascending / pathology. Colon, Transverse / pathology. Colonic Neoplasms / pathology. Colonoscopy. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenoma / pathology. Adenoma / radiography. Colectomy. Contrast Media. Humans. Logistic Models. Preoperative Care. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.
  • (PMID = 19930147.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


22. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F: Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res; 2008 Oct 15;68(20):8541-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.
  • The CpG island methylator phenotype (CIMP) is a distinct phenotype in colorectal cancer, associated with specific clinical, pathologic, and molecular features.
  • In our study, we defined three different subgroups of methylation (No-CIMP, CIMP-Low, and CIMP-High) and evaluated the prognostic significance of methylation status on a population-based series of sporadic colon cancers.
  • A total of 582 colon adenocarcinomas were evaluated using methylation-specific PCR for 5 markers (hMLH1, P16, MINT1, MINT2, and MINT31).
  • A shorter 5-year survival was observed in MSS cancer patients with CIMP-Low or CIMP-High status.
  • Methylation is an independent prognostic factor in MSS colon cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. CpG Islands. DNA Methylation

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18922929.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


23. Sastre J, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S, García-Saenz JA, Vidaurreta M, Martín M, Arroyo M, Sanz-Casla MT, Díaz-Rubio E: Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol; 2008 May;19(5):935-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.
  • BACKGROUND: The CellSearch System is a technique to detect circulating tumor cells (CTCs) in patients with cancer.
  • Few data have been published concerning the role of CTCs detection by this method in colorectal cancer.
  • CONCLUSIONS: CTCs detection by CellSearch is a highly reproducible method that correlates with stage but not with other clinical and morphological variables in patients with colorectal cancer.
  • Colon cancer tumor cells are detectable in all stages.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212090.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


24. Hofmanová J, Zadák Z, Hyspler R, Mikeska J, Zdánský P, Vaculová A, Netíková J, Kozubík A: The effects of parenteral lipid emulsions on cancer and normal human colon epithelial cells in vitro. Physiol Res; 2005;54(4):409-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of parenteral lipid emulsions on cancer and normal human colon epithelial cells in vitro.
  • In this study, the in vitro effects of five types of commercial parenteral lipid emulsions were investigated on human cell lines derived from normal fetal colon (FHC) or colon adenocarcinoma (HT-29).
  • Our results imply that lipid emulsions can differently affect the response of colon cells of distinct origin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Soybean oil .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15588151.001).
  • [ISSN] 0862-8408
  • [Journal-full-title] Physiological research
  • [ISO-abbreviation] Physiol Res
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Fat Emulsions, Intravenous; 0 / Fatty Acids; 0 / Reactive Oxygen Species; 0 / Triglycerides; 8001-22-7 / Soybean Oil
  •  go-up   go-down


25. Koizumi Y, Tomoda H, Kumagai A, Zhou XP, Koyota S, Sugiyama T: Simaomicin α, a polycyclic xanthone, induces G₁ arrest with suppression of retinoblastoma protein phosphorylation. Cancer Sci; 2009 Feb;100(2):322-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent progress in cancer biology research has shown that abnormal proliferation in tumor cells can be attributed to aberrations in cell cycle regulation, especially in G₁ phase.
  • Cell cycle aberrations induced by simaomicin α were also detected in colon adenocarcinoma HCT15 cells.
  • These results indicate that the polycyclic xanthones, including simaomicin α and cervinomycin A1, may be candidate cancer chemotherapeutic agents.

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077005.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoquinolines; 0 / Retinoblastoma Protein; 100157-22-0 / simaomicin alpha
  •  go-up   go-down


26. Mousa SA, Mohamed S, Wexler EJ, Kerr JS: Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist. Anticancer Res; 2005 Jan-Feb;25(1A):197-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RP747 demonstrated antitumor efficacy in 1 spontaneous tumor model (c-neu oncomouse model, alphavbeta3 positive cells) and in 1 xenograft model (HCT116 human tumor colon carcinoma, alphavbeta3 negative cells) injected subcutaneously into nude mice.
  • [MeSH-major] Adenocarcinoma / drug therapy. Angiogenesis Inhibitors / pharmacology. Colonic Neoplasms / drug therapy. Heterocyclic Compounds, 1-Ring / pharmacology. Integrin alphaVbeta3 / antagonists & inhibitors. Mammary Neoplasms, Experimental / drug therapy. Sulfonamides / pharmacology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816539.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antigens, CD31; 0 / Heterocyclic Compounds, 1-Ring; 0 / Integrin alphaVbeta3; 0 / Sulfonamides; 0 / TA 138
  •  go-up   go-down


27. Konski A, Li T, Sigurdson E, Cohen SJ, Small W Jr, Spies S, Yu JQ, Wahl A, Stryker S, Meropol NJ: Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys; 2009 May 1;74(1):55-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation.
  • PURPOSE: To correlate changes in 2-deoxy-2-[18F]fluoro-d-glucose (18-FDG) positron emission tomography (PET) (18-FDG-PET) uptake with response and disease-free survival with combined modality neoadjuvant therapy in patients with locally advanced rectal cancer.
  • METHODS AND MATERIALS: Charts were reviewed for consecutive patients with ultrasound-staged T3x to T4Nx or TxN1 rectal adenocarcinoma who underwent preoperative chemoradiation therapy at Fox Chase Cancer Center (FCCC) or Robert H.
  • Lurie Comprehensive Cancer Center of Northwestern University with 18-FDG-PET scanning before and after combined-modality neoadjuvant chemoradiation therapy .
  • CONCLUSIONS: A trend was observed for % SUV decrease and posttreatment SUV predicting pCR in patients with rectal cancer treated with preoperative chemoradiation therapy.
  • Further prospective study with a larger sample size is warranted to better characterize the role of 18-FDG-PET for response prediction in patients with rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):18-24 [10813118.001]
  • [Cites] Ann Nucl Med. 2002 Sep;16(6):409-16 [12416580.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):528-35 [14751524.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):279-86 [14991488.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):900-8 [14990646.001]
  • [Cites] J Am Coll Surg. 2004 Jul;199(1):1-7 [15217621.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31(6):811-9 [14762698.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8 [15383798.001]
  • [Cites] Biomed Pharmacother. 2004 Oct;58(8):451-7 [15464875.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1123-8 [15752892.001]
  • [Cites] Eur Radiol. 2005 Aug;15(8):1658-66 [15806369.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S63-7 [16399435.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):W202-8 [16861513.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1241-8 [16883000.001]
  • (PMID = 19004571.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA006927-449005; United States / NCI NIH HHS / CA / P30 CA006927-449005
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0W860991D6 / Deoxycytidine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 50SG953SK6 / Mitomycin; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS111700; NLM/ PMC2933375
  •  go-up   go-down


28. Pocard M, Sideris L, Zenasni F, Duvillard P, Boige V, Goéré D, Elias D, Malka D, Ducreux M, Lasser P: Functional results and quality of life for patients with very low rectal cancer undergoing coloanal anastomosis or perineal colostomy with colonic muscular graft. Eur J Surg Oncol; 2007 May;33(4):459-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional results and quality of life for patients with very low rectal cancer undergoing coloanal anastomosis or perineal colostomy with colonic muscular graft.
  • BACKGROUND: The aim of this study was to compare functional results and quality of life (QoL) of two salvage techniques: coloanal anastomosis (CAA) or perineal reconstruction after abdominoperineal resection for very low rectal cancer.
  • METHODS: Between 1991 and 2001, 50 patients were operated for a very low rectal adenocarcinoma and analyzed after a follow-up greater than one year and because there was no relapse or no treatment, they were included in the analysis.
  • [MeSH-major] Anal Canal / surgery. Anastomosis, Surgical / methods. Colon / surgery. Colostomy / methods. Muscle, Smooth / transplantation. Quality of Life. Recovery of Function. Rectal Neoplasms / physiopathology. Rectal Neoplasms / surgery. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123774.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Murakami J, Lee YJ, Kokeguchi S, Tsujigiwa H, Asaumi J, Nagatsuka H, Fukui K, Kuroda M, Tanaka N, Matsubara N: Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol Rep; 2007 Jun;17(6):1461-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines.
  • We have previously shown that the colorectal cancer patients treated with 5-fluorouracil (5-FU) as adjuvant chemotherapy had a better prognosis when the tumor revealed hypermethylation in its MGMT promoter.
  • Therefore, we sought to investigate the relationship between the expression levels of MGMT and the anti-tumor effect of 5-FU in vitro by using two colon adenocarcinoma and four oral cancer cell lines with a variety of MGMT expression.
  • Assessment of the levels of MGMT expression in cancer cells and the control of its expression could contribute to the effective chemotherapy by 5-FU especially in patients who previously were considered as low-responsive individuals whose tumors have high levels of MGMT.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Colonic Neoplasms / enzymology. Enzyme Inhibitors / pharmacology. Fluorouracil / pharmacology. Guanine / analogs & derivatives. Mouth Neoplasms / enzymology. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487405.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Ruys AT, Alderlieste YA, Gouma DJ, Dekker E, Mathus-Vliegen EM: Jejunal cancer in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol; 2010 Aug;8(8):731-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jejunal cancer in patients with familial adenomatous polyposis.
  • Surveillance and prophylactic treatment of colonic and duodenal manifestations of this disease have much influenced disease course and survival.
  • In more recent years, it has become clear that adenoma formation in FAP patients is not restricted to the colon and duodenum.
  • CONCLUSIONS: Jejunal adenomas in FAP patients are reported occasionally and can progress into adenocarcinoma with a poor prognosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Adenomatous Polyposis Coli / complications. Jejunal Neoplasms / diagnosis


31. Ruiz N, Fernandez-Martos C, Romero I, Pla A, Maiquez J, Calatrava A, Guillem V: Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol; 2007 Aug 1;25(22):3376-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / adverse effects. Colonic Neoplasms / drug therapy. Fusarium / isolation & purification. Mycoses / chemically induced. Nasal Septum / microbiology. Nose Diseases / microbiology

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17664487.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


32. Lai-Cheong JE, Groves RW, Banerjee P: Linear IgA bullous dermatosis associated with adenocarcinoma of the ascending colon. J Eur Acad Dermatol Venereol; 2007 Aug;21(7):978-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear IgA bullous dermatosis associated with adenocarcinoma of the ascending colon.
  • [MeSH-major] Adenocarcinoma / complications. Colonic Neoplasms / complications. Skin Diseases, Vesiculobullous / complications

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659011.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunoglobulin A
  •  go-up   go-down


33. Bulajic M, Stimec B, Ille T, Jesenofsky R, Kecmanovic D, Pavlov M, Ceranic M, Schneider-Brachert W, Lowenfels A, Maisonneuve P, Löhr J: PCR detection of helicobacter pylori genome in colonic mucosa: normal and malignant. Prilozi; 2007 Dec;28(2):25-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCR detection of helicobacter pylori genome in colonic mucosa: normal and malignant.
  • BACKGROUND AND AIMS: The aim of this study was to detect Helicobacter pylori (H. pylori) in colorectal cancer tissue specimens and relate the possible role of this microorganism in the etiology of colorectal cancer.
  • Pathology confirmed adenocarcinoma in all the CRC patients.
  • RESULTS: H. pylori PCR was positive in 1 case (1.2%) of CRC in the tumour tissue and in all 5 samples (6.0%) of the normal colonic mucosa in the cancer patients.
  • The K-ras PCR showed gene mutations in 19 tumour tissues of CRC (31.6%) and in 2 cases (3.4%) of normal colonic mucosa of CRC patients .

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356777.001).
  • [ISSN] 0351-3254
  • [Journal-full-title] Prilozi
  • [ISO-abbreviation] Prilozi
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.5.1.5 / Urease
  •  go-up   go-down


34. Sheng LM, Zhang LZ, Xu HM, Zhu Y: Ascending colon adenocarcinoma with tonsillar metastasis: a case report and review of the literature. World J Gastroenterol; 2008 Dec 14;14(46):7138-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ascending colon adenocarcinoma with tonsillar metastasis: a case report and review of the literature.
  • Metastatic palatine tonsil cancer is extremely rare, with nearly 100 such tumors reported in the English literature.
  • The prognosis of metastatic palatine tonsil cancer is poor.
  • A 53-year-old man presented with painless left palatine tonsillar swelling and a cervical mass following right hemicolectomy for an ascending colon adenocarcinoma.
  • A punch biopsy was taken for histological examination which showed a moderately-differentiated adenocarcinoma.
  • Our case shows that immunohistochemical diagnosis of metastatic palatine tonsil cancer is essential.
  • [MeSH-major] Adenocarcinoma / pathology. Colon, Ascending / pathology. Colonic Neoplasms / pathology. Tonsillar Neoplasms / diagnosis. Tonsillar Neoplasms / secondary

  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for colon adenocarcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):328-30 [11373114.001]
  • [Cites] Nucl Med Rev Cent East Eur. 2007;10(1):12-5 [17694495.001]
  • [Cites] J Laryngol Otol. 1999 Nov;113(11):1036-8 [10696391.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2000 Aug;20(4):281-3 [11234447.001]
  • [Cites] J Laryngol Otol. 1971 Mar;85(3):289-92 [5576091.001]
  • [Cites] Otolaryngol Clin North Am. 1979 Feb;12(1):29-43 [220581.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1979 Mar-Apr;88(2 Pt 1):235-40 [443718.001]
  • [Cites] J Laryngol Otol. 1994 May;108(5):449-51 [8035134.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1996 Sep;58(3):209-12 [8940794.001]
  • [Cites] Otolaryngol Head Neck Surg. 1997 Apr;116(4):563-4 [9141413.001]
  • [Cites] J Otolaryngol. 1997 Oct;26(5):325-6 [9343772.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):439-40 [10419718.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Sep;108(9):876-9 [10527279.001]
  • [Cites] Gastroenterol Clin Biol. 2005 Jan;29(1):70-2 [15738898.001]
  • [Cites] Clin Colorectal Cancer. 2005 Jul;5(2):108-13 [16098251.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Aug;53(8):455-7 [16164261.001]
  • [Cites] Auris Nasus Larynx. 2006 Mar;33(1):85-8 [16169179.001]
  • [Cites] Otolaryngol Pol. 2006;60(1):97-100 [16821552.001]
  • [Cites] J Otolaryngol. 2006 Aug;35(4):227-34 [17176797.001]
  • [Cites] Community Dent Oral Epidemiol. 2007 Apr;35(2):98-108 [17331151.001]
  • [Cites] Arch Bronconeumol. 2007 Jun;43(6):309-16 [17583640.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Nov;121(5):653-4 [10547490.001]
  • (PMID = 19084924.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 23
  • [Other-IDs] NLM/ PMC2776847
  •  go-up   go-down


35. Wang X, Yang W, Yang J: Extramammary Paget's disease with the appearance of a nodule: a case report. BMC Cancer; 2010;10:405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Epidermis / pathology. Paget Disease, Extramammary / pathology. Vulvar Diseases / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2000 Jan;142(1):59-65 [10651695.001]
  • [Cites] Pathol Res Pract. 2009;205(2):131-5 [18842349.001]
  • [Cites] J Urol. 2001 Dec;166(6):2112-6; discussion 2117 [11696717.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dermatol Surg. 2004 Oct;30(10):1329-34 [15458530.001]
  • [Cites] Cancer. 1976 Dec;38(6):2570-4 [187318.001]
  • [Cites] Cancer. 1977 Jun;39(6):2540-9 [194667.001]
  • [Cites] Am J Surg Pathol. 1977 Sep;1(3):193-206 [200150.001]
  • [Cites] Am J Dermatopathol. 1979 Summer;1(2):101-32 [232972.001]
  • [Cites] Plast Reconstr Surg. 1982 Feb;69(2):238-44 [6275432.001]
  • [Cites] Arch Pathol Lab Med. 1984 Sep;108(9):713-6 [6205637.001]
  • [Cites] Arch Dermatol. 1985 Jun;121(6):750-2 [2408584.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2234-8 [3052783.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):73-8 [1324902.001]
  • [Cites] J Cutan Pathol. 1994 Apr;21(2):157-63 [8040464.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):313-8 [18028492.001]
  • [Cites] J Clin Pathol. 2000 Oct;53(10):742-9 [11064666.001]
  • (PMID = 20684770.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2921398
  •  go-up   go-down


36. Okada K, Shatari T, Sasaki T, Tamada T, Suwa T, Furuuchi T, Takenaka Y, Hori M, Sakuma M: Is histopathological evidence really essential for making a surgical decision about mucinous carcinoma arising in a perianal fistula? Report of a case. Surg Today; 2008;38(6):555-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an unusual case of mucinous adenocarcinoma of the anus associated with a chronic anal fistula, treated successfully by abdominoperineal resection (APR).
  • Although multiple biopsies failed to reveal any histological evidence of malignancy, cancer was diagnosed from the mucin obtained for cytology.
  • Subsequent histological examination of the resected specimen revealed clusters of cancer cells floating in a mucous lake, suggesting that it would have been difficult to acquire the cells in a biopsy sample.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Anus Neoplasms / pathology. Anus Neoplasms / surgery. Rectal Fistula / complications

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1966 Sep-Oct;9(5):371-6 [5958587.001]
  • [Cites] Tech Coloproctol. 2006 Mar;10(1):51-3 [16528482.001]
  • [Cites] Hum Pathol. 1981 Nov;12(11):1034-7 [6274783.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):517-21 [16861558.001]
  • [Cites] Endoscopy. 1997 May;29(4):335 [9255549.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1511-2 [9407995.001]
  • [Cites] Postgrad Med J. 1987 Jun;63(740):503-4 [2829151.001]
  • [Cites] Chir Ital. 1999 Sep-Oct;51(5):413-6 [10738618.001]
  • [Cites] Ir Med J. 1984 Oct;77(10):326 [6094391.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s138-40 [15655599.001]
  • [Cites] Dis Colon Rectum. 1981 Oct;24(7):562-6 [6271516.001]
  • [Cites] Am J Surg. 1948 Feb;75(2):285-9 [18907412.001]
  • [Cites] Tech Coloproctol. 2006 Oct;10 (3):249-52 [16969607.001]
  • [Cites] Med J Malaysia. 2006 Mar;61(1):88-90 [16708740.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Apr;98(4):310-2 [16792461.001]
  • [Cites] Histopathology. 1984 Mar;8(2):279-92 [6327491.001]
  • [Cites] Acta Pathol Jpn. 1984 May;34(3):649-54 [6087605.001]
  • [Cites] Mil Med. 1986 Oct;151(10):543-6 [3022189.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1163-5 [1682590.001]
  • [Cites] Am Surg. 2003 Feb;69(2):166-9 [12641361.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):2053-4 [12942309.001]
  • (PMID = 18516539.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Landmann RG, Wong WD, Hoepfl J, Shia J, Guillem JG, Temple LK, Paty PB, Weiser MR: Limitations of early rectal cancer nodal staging may explain failure after local excision. Dis Colon Rectum; 2007 Oct;50(10):1520-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limitations of early rectal cancer nodal staging may explain failure after local excision.
  • Successful selection of patients with rectal cancer for local excision requires accurate preoperative lymph node staging.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / ultrasonography. Endosonography. Neoplasm Staging / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674104.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL: High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol; 2009 Jul;175(1):355-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-alcoholic fatty liver disease (NAFLD), which includes steatosis and its progression to non-alcoholic steatohepatitis, is a liver disorder of increasing clinical significance.
  • Importantly, we extend these studies to demonstrate that even the early stages of uncomplicated steatosis provide a permissive microenvironment for the growth of colon cancer cells that are metastatic to the liver.
  • High fat diet-induced steatosis, coupled with a splenic injection model of experimental liver metastasis using syngeneic MC38 colon cancer cells, resulted in an increased number of secondary tumor nodules and metastatic burden in steatotic livers.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2007 Sep;42(9):1023-30 [17710666.001]
  • [Cites] Nutr Rev. 2007 Jun;65(6 Pt 2):S57-63 [17605315.001]
  • [Cites] Curr Opin Lipidol. 2008 Feb;19(1):25-9 [18196983.001]
  • [Cites] Clin Sci (Lond). 2008 Apr;114(7):457-66 [18302533.001]
  • [Cites] Curr Drug Targets. 2008 May;9(5):375-80 [18473765.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(2):329-42 [17939036.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):204-15 [18448242.001]
  • [Cites] Cytokine. 2008 Sep;43(3):374-9 [18701317.001]
  • [Cites] Arch Pathol Lab Med. 2008 Nov;132(11):1761-6 [18976012.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1079-90 [18953558.001]
  • [Cites] Digestion. 2009;79 Suppl 1:26-32 [19153487.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):163-76 [10652271.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Semin Liver Dis. 2001;21(1):89-104 [11296700.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5016-23 [11431335.001]
  • [Cites] Eur J Immunol. 2001 Jul;31(7):1981-8 [11449350.001]
  • [Cites] Jpn J Cancer Res. 2002 Feb;93(2):125-32 [11856475.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):679-90 [12406439.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):1-10 [12925950.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):114-8 [15221653.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):60-6 [15246209.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S97-103 [15508109.001]
  • [Cites] Cancer Res. 1980 Jul;40(7):2083-128 [7388781.001]
  • [Cites] Lab Invest. 1988 Dec;59(6):848-56 [2462130.001]
  • [Cites] Am J Pathol. 1989 Mar;134(3):505-13 [2466401.001]
  • [Cites] Biochem J. 1997 Mar 15;322 ( Pt 3):809-14 [9148753.001]
  • [Cites] Liver Int. 2005 Apr;25(2):294-304 [15780053.001]
  • [Cites] J Leukoc Biol. 2005 Apr;77(4):552-9 [15629884.001]
  • [Cites] Obes Surg. 2005 Mar;15(3):442-6 [15826485.001]
  • [Cites] Diabetologia. 2005 Apr;48(4):634-42 [15747110.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 May;4(2):173-7 [15908310.001]
  • [Cites] Diabet Med. 2005 Sep;22(9):1129-33 [16108837.001]
  • [Cites] Front Biosci. 2006;11:479-91 [16146745.001]
  • [Cites] Eur Rev Med Pharmacol Sci. 2005 Sep-Oct;9(5):291-3 [16231592.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 [16447287.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1079-86 [17164441.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):495-500 [17417772.001]
  • [Cites] Clin Liver Dis. 2007 Feb;11(1):17-23, vii [17544969.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):830-9 [17211838.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):556-64 [17459514.001]
  • (PMID = 19541928.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50CA095103; United States / NCI NIH HHS / CA / P50 CA095103; United States / NIDDK NIH HHS / DK / P30 DK058404; United States / NCI NIH HHS / CA / R01CA060867; United States / NIDDK NIH HHS / DK / K08 DK70708-01; United States / NIDDK NIH HHS / DK / P30DK058404; United States / NIDDK NIH HHS / DK / K08 DK070708; United States / NCI NIH HHS / CA / R01 CA060867
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats
  • [Other-IDs] NLM/ PMC2708821
  •  go-up   go-down


39. Halevy A, Bracha M, Jeroukhimov I, Schneider D, Nesterenko V: En bloc resection for malignant colouterine fistula. Tech Coloproctol; 2010 Mar;14(1):37-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A literature search revealed only a few reports dealing with this complex problem, mostly resulting as a complication of diverticular disease of the colon.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Intestinal Fistula / etiology. Intestinal Fistula / surgery. Uterine Diseases / etiology. Uterine Diseases / surgery

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrasound Obstet Gynecol. 2004 Nov;24(6):682-3 [15476298.001]
  • [Cites] JAMA. 1969 Jan 20;207(3):555-7 [5818219.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2055-63 [15657654.001]
  • [Cites] Minerva Chir. 1998 Oct;53(10):827-30 [9882974.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Sep 10;110(1):107-10 [12932884.001]
  • (PMID = 20130950.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


40. Hanneken S, Kuerten V, Hoernke M, Neumann NJ: Metastatic colon cancer triggering an acute attack of variegate porphyria. Int J Colorectal Dis; 2009 Jan;24(1):127-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colon cancer triggering an acute attack of variegate porphyria.
  • [MeSH-major] Adenocarcinoma / complications. Ileal Neoplasms / complications. Porphyria, Variegate / etiology


41. García-Aguilar J, Hernández de Anda E, Rothenberger DA, Finne CO, Madoff RD: Endorectal ultrasound in the management of patients with malignant rectal polyps. Dis Colon Rectum; 2005 May;48(5):910-6; discussion 916-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective review of the medical records and endorectal ultrasound images of 63 patients with endoscopically removed rectal polyps containing invasive adenocarcinoma subsequently staged by endorectal ultrasound.
  • The accuracy of endorectal ultrasound in assessing the presence of residual cancer in the rectal wall in patients who had surgery was 54 percent, with a 39 percent positive predictive value and 65 percent negative predictive value.
  • Endorectal ultrasound was more useful than polyp morphologic or histologic criteria to determine the presence of residual cancer in the rectal wall.
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma / ultrasonography. Endosonography. Polyps / surgery. Polyps / ultrasonography. Rectal Neoplasms / surgery. Rectal Neoplasms / ultrasonography

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868240.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Aviello G, Rowland I, Gill CI, Acquaviva AM, Capasso F, McCann M, Capasso R, Izzo AA, Borrelli F: Anti-proliferative effect of rhein, an anthraquinone isolated from Cassia species, on Caco-2 human adenocarcinoma cells. J Cell Mol Med; 2010 Jul;14(7):2006-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-proliferative effect of rhein, an anthraquinone isolated from Cassia species, on Caco-2 human adenocarcinoma cells.
  • In recent years, the use of anthraquinone laxatives, in particular senna, has been associated with damage to the intestinal epithelial layer and an increased risk of developing colorectal cancer.
  • In this study, we evaluated the cytotoxicity of rhein, the active metabolite of senna, on human colon adenocarcinoma cells (Caco-2) and its effect on cell proliferation.
  • Rhein was devoid of cytotoxic and genotoxic effects in colon adenocarcinoma cells.
  • Moreover, at concentrations present in the colon after a human therapeutic dosage of senna, rhein inhibited cell proliferation via a mechanism that seems to involve directly the MAP kinase pathway.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538468.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthraquinones; YM64C2P6UX / rhein
  • [Other-IDs] NLM/ PMC3823282
  •  go-up   go-down


43. Odigie VI, Yusufu LM, Dawotola DA, Adebamowo C, Yakubu A, Garba ES, Khalides L, Shehu SM, Mohammed A, Samaila M: Anatomical subsite and diagnostic implications of colorectal cancer in zaria (Guinea savannah)-1981-2005. Niger Postgrad Med J; 2009 Mar;16(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomical subsite and diagnostic implications of colorectal cancer in zaria (Guinea savannah)-1981-2005.
  • OBJECTIVE: To study the clinicopathological characteristics of Colorectal Cancer (CRC) in the Guinea Savannah region; identify sub site; ascertain any change in the anatomical sub-site between 1981-2005; relate tumour stage/differentiation, to age young =40 years and = 41years old patients Highlight option for diagnosis in the sub region.
  • The left colon was eleven times more commonly affected than the right colon.
  • 97.2% the tumours were adenocarcinoma.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19305436.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


44. Wang L, Warner NE, Sherrod AE: Pathologic quiz case: a 79-year-old woman with a black, ulcerated cecal tumor and 3 negative guaiac test results. Medullary adenocarcinoma of the colon, poorly differentiated. Arch Pathol Lab Med; 2005 Jan;129(1):113-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic quiz case: a 79-year-old woman with a black, ulcerated cecal tumor and 3 negative guaiac test results. Medullary adenocarcinoma of the colon, poorly differentiated.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Medullary / diagnosis. Cecal Neoplasms / diagnosis. Colonic Neoplasms / diagnosis. Guaiac. Occult Blood. Ulcer / diagnosis

  • Hazardous Substances Data Bank. GUM GUAIAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628891.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9000-29-7 / Guaiac
  •  go-up   go-down


45. Rieck GC, Lim K, Rogers MT, France E, Gray JR, Amso N, Evans AS, Howells RH, Fiander AN: Screening for familial ovarian cancer--management and outcome of women with moderate to high risk of developing ovarian cancer. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:86-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for familial ovarian cancer--management and outcome of women with moderate to high risk of developing ovarian cancer.
  • Currently, prophylactic surgery is advised to women with a moderate to high risk of developing ovarian cancer.
  • The median age was 42 (SD 10.4), 71.7% were pre menopausal, and 10.3% had a personal history of breast cancer and 1.4% colon cancer.
  • Histology of the women who had surgery showed three cases of malignancies (fallopian tube carcinoma, atypical ovarian epithelial cells, and metastatic breast cancer).
  • Seven women developed breast cancer during the observation period.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Fallopian Tube Neoplasms / diagnosis. Neoplastic Syndromes, Hereditary / diagnosis. Ovarian Neoplasms / diagnosis. Precancerous Conditions / diagnosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515573.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Carvalho M, Silva BM, Silva R, Valentão P, Andrade PB, Bastos ML: First report on Cydonia oblonga Miller anticancer potential: differential antiproliferative effect against human kidney and colon cancer cells. J Agric Food Chem; 2010 Mar 24;58(6):3366-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First report on Cydonia oblonga Miller anticancer potential: differential antiproliferative effect against human kidney and colon cancer cells.
  • The present study reports the phenolic profile and antiproliferative properties of quince (Cydonia oblonga Miller) leaf and fruit (pulp, peel, and seed) against human kidney and colon cancer cells.
  • The extracts from quince leaf showed concentration-dependent growth inhibitory activity toward human colon cancer cells (IC(50) = 239.7 +/- 43.2 microg/mL), while no effect was observed in renal adenocarcinoma cells.
  • Concerning the fruit, seed extracts exhibited no effect on colon cancer cell growth, whereas strong antiproliferative efficiency against renal cancer cells was observed for the highest concentration assayed (500 microg/mL).
  • This is the first report showing that C. oblonga may be useful as a cancer chemopreventive and/or chemotherapeutic agent.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Colonic Neoplasms / physiopathology. Kidney Neoplasms / physiopathology. Plant Extracts / pharmacology. Rosaceae / chemistry

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192210.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down


47. Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, Saba-El-Leil MK, Rodrigue-Gervais IG, Gaboury L, Lamarre D, Basik M, Meloche S: Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer; 2008;8:337
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The Ras-dependent ERK1/2 MAP kinase signaling pathway plays a central role in cell proliferation control and is frequently activated in human colorectal cancer.
  • However, the exact contribution of MEK1 and MEK2 to the pathogenesis of colorectal cancer remains to be established.
  • RNA interference was used to test the requirement for MEK1 and MEK2 function in maintaining the proliferation of human colorectal cancer cells.
  • RESULTS: We found that expression of activated MEK1 or MEK2 is sufficient to morphologically transform intestinal epithelial cells, dysregulate cell proliferation and induce the formation of high-grade adenocarcinomas after orthotopic transplantation in mice.
  • Importantly, we show that silencing of MEK2 expression completely suppresses the proliferation of human colon carcinoma cell lines, whereas inactivation of MEK1 has a much weaker effect.
  • Our results suggest that MEK2 plays a more important role than MEK1 in sustaining the proliferation of human colorectal cancer cells.
  • [MeSH-major] Adenocarcinoma / secondary. Cell Transformation, Neoplastic. Intestinal Mucosa / pathology. Intestinal Neoplasms / pathology. MAP Kinase Kinase 1 / metabolism. MAP Kinase Kinase 2 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 May 14;26(22):3227-39 [17496918.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Int J Exp Pathol. 2008 Feb;89(1):1-12 [18081801.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):543-56 [10662779.001]
  • [Cites] Oncogene. 2000 Mar 23;19(13):1665-75 [10763823.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2686-92 [11031257.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):233-6 [12086859.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6023-33 [12167697.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4781-90 [12183438.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):469-80 [12579299.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8118-25 [12506122.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):395-403 [12884914.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):733-40 [12844146.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Aug;4(8):657-65 [12923528.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5669-73 [14522881.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6785-93 [14555991.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42615-24 [12915405.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):763-76 [14737111.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 May;286(5):G736-46 [14701721.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 May;5(5):355-66 [15122349.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):503-15 [15304090.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6035-40 [15342384.001]
  • [Cites] J Natl Cancer Inst. 1974 Sep;53(3):661-74 [4412247.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4562-9 [1000501.001]
  • [Cites] J Natl Cancer Inst. 1977 Jul;59(1):221-6 [327080.001]
  • [Cites] J Cell Biol. 1979 Feb;80(2):248-65 [88453.001]
  • [Cites] Br J Cancer. 1983 Mar;47(3):373-81 [6830688.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6863-71 [2846163.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cell. 1994 Jun 17;77(6):841-52 [7911739.001]
  • [Cites] Science. 1994 Aug 12;265(5174):966-70 [8052857.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7686-9 [7644477.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):3265-71 [8621729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6924-8 [8692920.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11426-33 [9111053.001]
  • [Cites] Mol Endocrinol. 1997 Oct;11(11):1618-25 [9328344.001]
  • [Cites] Gastroenterology. 1997 Nov;113(5):1589-98 [9352861.001]
  • [Cites] J Cell Physiol. 1998 Jan;174(1):35-47 [9397154.001]
  • [Cites] Curr Opin Oncol. 1999 Jan;11(1):68-75 [9914881.001]
  • [Cites] Nucleic Acids Res. 1999 May 15;27(10):2086-90 [10219080.001]
  • [Cites] Cell Growth Differ. 1999 May;10(5):317-32 [10359013.001]
  • [Cites] Nat Med. 1999 Jul;5(7):810-6 [10395327.001]
  • [Cites] Virology. 1964 Jun;23:291-4 [14187925.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):298-306 [15549091.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):937-47 [15573115.001]
  • [Cites] J Cell Biol. 2005 Jan 3;168(1):55-66 [15631990.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):322-7 [15863380.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):577-90 [16083714.001]
  • [Cites] Front Biosci. 2006;11:479-91 [16146745.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):103-14 [16098678.001]
  • [Cites] Mol Cancer. 2006;5:63 [17112382.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2040-8 [18003960.001]
  • (PMID = 19014680.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; EC 2.7.1.- / MAP2K1 protein, human; EC 2.7.1.- / MAP2K2 protein, human; EC 2.7.12.2 / MAP Kinase Kinase 1; EC 2.7.12.2 / MAP Kinase Kinase 2; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2596176
  •  go-up   go-down


48. Haase C, Bergmann R, Oswald J, Zips D, Pietzsch J: Neurotensin receptors in adeno- and squamous cell carcinoma. Anticancer Res; 2006 Sep-Oct;26(5A):3527-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Peptide receptors seem to be good markers for receptor targeting because of their overexpression in human cancer.
  • The expression of NTR in HT-29 cells (human colon adenocarcinoma cell line), FaDu cells (human squamous cell carcinoma cell line) and in corresponding tumor xenografts on nude mice, was investigated.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Receptors, Neurotensin / metabolism
  • [MeSH-minor] Animals. Butyrates / pharmacology. Cell Differentiation. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. Female. HT29 Cells. Humans. Hypopharyngeal Neoplasms / genetics. Hypopharyngeal Neoplasms / metabolism. Male. Mice. Mice, Nude. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094477.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Butyrates; 0 / NTSR2 protein, human; 0 / Ntsr2 protein, mouse; 0 / Receptors, Neurotensin; 0 / neurotensin type 1 receptor
  •  go-up   go-down


49. de Leng WW, Keller JJ, Luiten S, Musler AR, Jansen M, Baas AF, de Rooij FW, Gille JJ, Menko FH, Offerhaus GJ, Weterman MA: STRAD in Peutz-Jeghers syndrome and sporadic cancers. J Clin Pathol; 2005 Oct;58(10):1091-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: LKB1 is a tumour suppressor gene that is associated with Peutz-Jeghers syndrome (PJS), a rare autosomal dominant cancer predisposition syndrome.
  • METHODS: The involvement of STRAD in 42 PJS associated tumours (sporadic lung, colon, gastric, and ovarian adenocarcinomas) was studied using loss of heterozygosity (LOH) analysis of eight microsatellite markers on chromosome 17, including TP53, BRCA1, and STRAD markers.
  • RESULTS: Loss of the marker near the STRAD locus was seen in 13 of 29 informative cases, including all gastric adenocarcinomas.
  • CONCLUSIONS: Despite the frequent occurrence of LOH in the STRAD region, these results indicate that inactivation of the STRAD gene is not essential in the sporadic adenocarcinomas studied, although it is possible that STRAD may be inactivated in different ways.
  • [MeSH-major] Adaptor Proteins, Vesicular Transport / genetics. Adenocarcinoma / genetics. Neoplasm Proteins / genetics. Peutz-Jeghers Syndrome / genetics
  • [MeSH-minor] Chromosomes, Human, Pair 17 / genetics. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. DNA, Neoplasm / genetics. Female. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Loss of Heterozygosity. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Microsatellite Repeats. Mutation. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4729-34 [10987277.001]
  • [Cites] Am J Hum Genet. 1997 Dec;61(6):1327-34 [9399902.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1307-19 [11430832.001]
  • [Cites] Hum Mol Genet. 2001 Dec 1;10(25):2869-77 [11741830.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):61-7 [11773283.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3925-8 [12124320.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Oct;27(4):495-502 [12356584.001]
  • [Cites] Cytogenet Genome Res. 2002;97(3-4):171-8 [12438709.001]
  • [Cites] EMBO J. 2003 Jun 16;22(12):3062-72 [12805220.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):308-13 [12865922.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4752-6 [12879020.001]
  • [Cites] Nat Cell Biol. 2003 Oct;5(10):889-94 [12973359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3329-35 [14985505.001]
  • [Cites] Cell. 2004 Feb 6;116(3):457-66 [15016379.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Feb;2(2):147-56 [15017620.001]
  • [Cites] Nat Genet. 2004 May;36(5):497-501 [15064764.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1788-94 [15188174.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Cancer. 1982 Oct 1;50(7):1384-402 [7104978.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1511-4 [3587280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9252-6 [2892196.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5 [8506342.001]
  • [Cites] Br J Cancer. 1993 Jun;67(6):1262-7 [8512811.001]
  • [Cites] Hum Genet. 1996 Aug;98(2):125-8 [8698325.001]
  • [Cites] Int J Oncol. 1998 Jun;12(6):1245-51 [9592181.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):119-23 [9666805.001]
  • [Cites] Oncogene. 1998 Dec 10;17(23):3029-33 [9881705.001]
  • [Cites] Oncogene. 1999 Mar 4;18(9):1777-80 [10208439.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9248-51 [10430928.001]
  • [Cites] N Engl J Med. 1949 Dec 29;241(26):1031-6 [15398245.001]
  • [Cites] J Clin Pathol. 2004 Dec;57(12):1312-8 [15563674.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1592-7 [8932340.001]
  • [Cites] Nat Genet. 1997 Jan;15(1):87-90 [8988175.001]
  • [Cites] Hum Genet. 1997 Oct;100(5-6):515-9 [9341864.001]
  • [Cites] Br J Cancer. 1998;77(2):277-86 [9460999.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • (PMID = 16189157.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Vesicular Transport; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / STRAD protein, human
  • [Other-IDs] NLM/ PMC1770744
  •  go-up   go-down


50. Bilimoria KY, Stewart AK, Palis BE, Bentrem DJ, Talamonti MS, Ko CY: Adequacy and importance of lymph node evaluation for colon cancer in the elderly. J Am Coll Surg; 2008 Feb;206(2):247-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adequacy and importance of lymph node evaluation for colon cancer in the elderly.
  • BACKGROUND: Studies have demonstrated improved survival when 12 or more nodes are examined for colon cancer.
  • The elderly comprise a major proportion of patients with colon cancer, but it is unknown if examination of 12 or more nodes is appropriate for older patients.
  • STUDY DESIGN: From the National Cancer Data Base (1998 to 2004), we identified 142,009 N0M0 patients who underwent colectomy for adenocarcinoma.
  • CONCLUSIONS: The elderly account for nearly half of patients with colon cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Age Factors. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Lymph Node Excision

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222376.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. van der Woude CJ, Moshage H, Homan M, Kleibeuker JH, Jansen PL, van Dekken H: Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis. J Clin Pathol; 2005 Aug;58(8):811-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chronic ulcerative colitis (CUC) is associated with increased risk of developing colon cancer through a dysplasia (intraepithelial neoplasia)-carcinoma sequence.
  • METHODS: The expression of proteins involved in apoptosis and inflammation (inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2), Bcl-xl, Fas, and active caspase 3) was investigated and compared with that seen in sporadic colon carcinoma.
  • Compared with CUC associated carcinoma, iNOS was consistently expressed in sporadic colon carcinoma cells, whereas Bcl-xl was almost absent in these tumour cells and Fas was only weakly expressed.
  • These results support a causal role for chronic inflammation in cancer development in CUC, and treatment of ulcerative colitis should aim to minimise inflammation.
  • [MeSH-major] Apoptosis. Colitis, Ulcerative / metabolism. Colonic Neoplasms / metabolism. Neoplasm Proteins / metabolism. Precancerous Conditions / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antigens, CD95 / metabolism. Caspase 3. Caspases / metabolism. Cyclooxygenase 2. Disease Progression. Female. Humans. Inflammation Mediators / metabolism. Male. Membrane Proteins. Middle Aged. Nitric Oxide Synthase / metabolism. Nitric Oxide Synthase Type II. Prostaglandin-Endoperoxide Synthases / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-X Protein

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Mar;31(3):288-91 [10746669.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):131-6 [9490271.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):190-9 [11208728.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G626-34 [11518674.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):686-92 [12196918.001]
  • [Cites] Apoptosis. 2004 Mar;9(2):123-30 [15004509.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Gastroenterology. 1990 Aug;99(2):416-20 [2194896.001]
  • [Cites] Gut. 1990 Jul;31(7):800-6 [2370015.001]
  • [Cites] Gastroenterology. 1992 Nov;103(5):1602-10 [1358743.001]
  • [Cites] Z Gastroenterol. 1993 Mar;31(3):192-7 [8386413.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2261-3 [8940994.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3452-7 [11151876.001]
  • (PMID = 16049281.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / BCL2L1 protein, human; 0 / Inflammation Mediators; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1770877
  •  go-up   go-down


52. Ding W, Ju S, Jiang S, Zhu L, Wang Y, Wang H: Reduced APRIL expression induces cellular senescence via a HSPG-dependent pathway. Pathol Oncol Res; 2009 Dec;15(4):693-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we analyzed APRIL and HSPG expression in the colon carcinoma cell line, SW480 by Western blot and RT-PCR.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Aging / physiology. Colonic Neoplasms / metabolism. Heparan Sulfate Proteoglycans / metabolism. Signal Transduction / physiology. Tumor Necrosis Factor Ligand Superfamily Member 13 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1998 Sep 21;188(6):1185-90 [9743536.001]
  • [Cites] Cell Death Differ. 2001 Apr;8(4):403-10 [11550092.001]
  • [Cites] J Immunol. 2002 Oct 15;169(8):4314-21 [12370363.001]
  • [Cites] Exp Gerontol. 2005 Oct;40(10):836-8 [16181758.001]
  • [Cites] Annu Rev Immunol. 2003;21:231-64 [12427767.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):997-1006 [14729948.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1677-84 [11104810.001]
  • [Cites] Biogerontology. 2004;5(1):1-10 [15138376.001]
  • [Cites] Mol Biol Cell. 2006 Apr;17(4):1583-92 [16436515.001]
  • [Cites] Biochem Pharmacol. 2003 Oct 15;66(8):1403-8 [14555214.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35478-85 [10956646.001]
  • [Cites] J Exp Med. 2005 Nov 21;202(10 ):1363-74 [16301744.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):7218-27 [15542592.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2108-11 [11509692.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1324-7 [17315017.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1375-83 [15851487.001]
  • [Cites] Nat Rev Drug Discov. 2006 Mar;5(3):235-46 [16474316.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6736-51 [16709833.001]
  • [Cites] Semin Immunol. 2006 Oct;18(5):305-17 [16916610.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):961-76 [15743671.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2005 May;14(3):243-8 [15821417.001]
  • [Cites] Exp Gerontol. 2001 Aug;36(8):1327-47 [11602208.001]
  • [Cites] Curr Biol. 2000 Jun 29;10(13):785-8 [10898980.001]
  • [Cites] Blood. 2007 Jan 15;109(2):729-39 [16960154.001]
  • [Cites] Braz J Med Biol Res. 2006 Feb;39(2):157-67 [16470302.001]
  • [Cites] N Engl J Med. 1996 Jun 27;334(26):1717-25 [8637518.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1012-20 [15860672.001]
  • [Cites] J Mol Biol. 2004 Oct 15;343(2):283-90 [15451660.001]
  • [Cites] Blood. 2007 Jan 1;109(1):331-8 [17190854.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):637-48 [15846369.001]
  • [Cites] Blood. 2007 Jan 15;109(2):703-10 [16973958.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):3005-12 [14691452.001]
  • [Cites] Genes Cells. 2003 Feb;8(2):131-44 [12581156.001]
  • [Cites] EMBO Rep. 2001 Oct;2(10):945-51 [11571266.001]
  • (PMID = 19466596.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Heparan Sulfate Proteoglycans; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13
  •  go-up   go-down


53. Sung HY, Cheung DY, Cho SH, Kim JI, Park SH, Han JY, Park GS, Kim JK, Chung IS: Polyps in the gastrointestinal tract: discrepancy between endoscopic forceps biopsies and resected specimens. Eur J Gastroenterol Hepatol; 2009 Feb;21(2):190-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this prospective study was to determine the diagnostic concordance between an EFB and resected tissues of gastric and colon polyps.
  • One thousand two hundred and sixty-four polyps of epithelial origin [gastric polyps (n=268) and colon polyps (n=996)] obtained from 813 patients met the inclusion criteria.
  • The pathological diagnoses of resected gastric polyps were as follows: adenomas with low-grade dysplasia, 46 (17.2%); adenomas with high-grade dysplasia, 42 (15.7%); hyperplastic polyps, 126 (47.0%); chronic inflammatory polyps, 29 (10.8%); and adenocarcinomas, 25 (9.3%).
  • The pathological diagnoses of the resected colon polyps were as follows: adenomas with low-grade dysplasia, 559 (56.1%); adenomas with high-grade dysplasia, 229 (23.0%); hyperplastic polyps, 44 (4.4%); adenocarcinomas, 53 (5.3%); and inflammatory polyps, 111 (11.1%).
  • The discrepancy rate between the EFB and the pathology of the resected colon polyps was 39.8%. (the Kendall's tau-b and the kappa coefficient for agreement between the EFB and the resected specimens of the colon polyps were 0.479 and 0.293, respectively; P value <0.001).
  • No relationship between the size of the colon polyp and the concordance rate was observed.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / pathology. Adenoma / surgery. Aged. Biopsy. Colonic Polyps / pathology. Colonic Polyps / surgery. Endoscopy, Gastrointestinal. Female. Humans. Male. Middle Aged. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Prospective Studies. Reproducibility of Results. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092673.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Kasashima S, Kawashima A, Zen Y: Invasive micropapillary carcinoma of the colon in ascitic fluid: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):803-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinoma of the colon in ascitic fluid: a case report.
  • Ascitic fluid cytology showed adenocarcinoma with papillary features, and a colectomy specimen showed IMPC.
  • Differentiation from adenocarcinoma of other organs may be difficult, but immunohistochemical profiles suggested a colorectal origin; it was positive for CK20 and negative for CK7.
  • [MeSH-major] Ascitic Fluid / pathology. Carcinoma, Papillary / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053544.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Pilarski R, Filip B, Wietrzyk J, Kuraś M, Gulewicz K: Anticancer activity of the Uncaria tomentosa (Willd.) DC. preparations with different oxindole alkaloid composition. Phytomedicine; 2010 Dec 1;17(14):1133-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The activity of Uncaria tomentosa preparations on cancer cells was studied using in vitro and in vivo models.
  • B/96E(37) were shown to be active against Lewis lung carcinoma (LL/2) [IC(50) =25.06 μg/ml], cervical carcinoma (KB) [IC(50) =35.69 μg/ml] and colon adenocarcinoma (SW707) [IC(50) =49.06 μg/ml].

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20576410.001).
  • [ISSN] 1618-095X
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents, Phytogenic; 0 / Indoles; 0 / Plant Extracts; 0 / oxindole
  •  go-up   go-down


56. Shen Z, Yang X, Chen L, Hao F, Zhong B: Sister Mary Joseph's nodule as a diagnostic clue to metastatic colon carcinoma. J Clin Oncol; 2009 Jul 1;27(19):e1-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sister Mary Joseph's nodule as a diagnostic clue to metastatic colon carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Umbilicus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433679.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


57. Soga K, Konishi H, Tatsumi N, Konishi C, Nakano K, Wakabayashi N, Mitsufuji S, Kataoka K, Okanoue T, Mukaisho K, Hattori T: Clear cell adenocarcinoma of the colon: a case report and review of literature. World J Gastroenterol; 2008 Feb 21;14(7):1137-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the colon: a case report and review of literature.
  • A primary clear cell adenocarcinoma of the colon is a rare oncologic entity.
  • We herein report a case of such a tumor of the sigmoid colon in a 71-year-old woman who was successfully treated by an endoscopic polypectomy in our hospital.
  • We also reviewed the published reports regarding cases of primary clear cell tumors in the colon.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1993 Jan;15(1):61-4 [8334942.001]
  • [Cites] Tumori. 1992 Jun 30;78(3):219-20 [1440947.001]
  • [Cites] Eur Urol. 1997;31(1):73-80 [9032539.001]
  • [Cites] Int J Urol. 1996 Nov;3(6):501-3 [9170582.001]
  • [Cites] Urology. 1997 Oct;50(4):636-42 [9338750.001]
  • [Cites] J Surg Oncol. 1998 Mar;67(3):182-5 [9530889.001]
  • [Cites] Urology. 1998 Jun;51(6):1057-61 [9609655.001]
  • [Cites] Eur Urol. 1999;35(3):242-8 [10072628.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1593-8 [10193951.001]
  • [Cites] Histopathology. 1999 Mar;34(3):250-6 [10217566.001]
  • [Cites] Surg Today. 1999;29(5):449-52 [10333418.001]
  • [Cites] Cancer. 1964 Feb;17:259-63 [14123687.001]
  • [Cites] Arch Esp Urol. 2000 Jan-Feb;53(1):79-81 [10730432.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1047-51 [11036280.001]
  • [Cites] J Clin Pathol. 2001 Jan;54(1):76-7 [11271795.001]
  • [Cites] Ann Ital Chir. 2000 Nov-Dec;71(6):643-7; discussion 647-8 [11347315.001]
  • [Cites] Urology. 2002 Apr;59(4):615-20 [11927338.001]
  • [Cites] Int J Colorectal Dis. 2004 May;19(3):264-7 [14557891.001]
  • [Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):259-70 [15086725.001]
  • [Cites] Union Med Can. 1976 Sep;105(9):1351-3 [969045.001]
  • [Cites] Obstet Gynecol. 1987 Oct;70(4):573-7 [3627626.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):197-9 [3276291.001]
  • [Cites] Am J Obstet Gynecol. 1990 Jan;162(1):161-3 [2301485.001]
  • [Cites] Gynecol Oncol. 1990 Dec;39(3):314-20 [2258077.001]
  • [Cites] J Clin Pathol. 1995 Dec;48(12):1142-4 [8568005.001]
  • (PMID = 18286700.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC2689421
  •  go-up   go-down


58. Wong NY, Koh PK, Eu KW: A novel method of dealing with a large rectal enterotomy in an irradiated pelvis. Tech Coloproctol; 2007 Dec;11(4):350-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pelvic irradiation as part of adjuvant therapy for rectal cancer is frought with many complications.
  • We describe the case of a young man who presented with frequent intestinal obstruction after resection and radiotherapy for a low rectal cancer.
  • A loop of sigmoid colon was used to cover the pelvic brim in an effort to preserve the sphincter and intestinal continuity.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Colectomy / methods. Colon / surgery. Pelvis / radiation effects. Rectal Neoplasms / radiotherapy. Rectum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Surg. 2000;17(3):216-8 [10867452.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1130-5 [9278661.001]
  • [Cites] Br J Surg. 1989 Jun;76(6):605-6 [2758269.001]
  • [Cites] Am J Surg. 2001 Apr;181(4):309-12 [11438264.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):403-18 [10223765.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • (PMID = 18209949.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


59. Gaedcke J, Gunawan B, Grade M, Szöke R, Liersch T, Becker H, Ghadimi BM: The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg; 2010 Apr;395(4):451-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials.
  • PURPOSE: The prognosis of patients with pancreatic cancer remains poor, even after potentially curative R0 resection.
  • RESULTS: Thirty-five patients were excluded from the analysis owing to the pathohistological diagnosis; only pancreatic ductal adenocarcinoma, distal bile duct adenocarcinoma, and periampullary adenocarcinoma were included.
  • Applying the International Union Against Cancer criteria, 32 cancer resections were classified R0 (49.2%), while 33 cases turned out to be R1 resections (50.8%).
  • CONCLUSION: Using the intensified histopathological workup for pancreatic head cancer specimens resulted in an increased rate of R1 resections and the mesopancreas represents the primary site for positive resection margins.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1651-60 [18351300.001]
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):954-64 [12788434.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):718-25; discussion 725-7 [15249403.001]
  • [Cites] Dig Surg. 2004;21(3):202-9 [15218236.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2118-23 [8104092.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):384-7 [8406311.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):653-9; discussion 660 [7676716.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):120-1 [9510323.001]
  • [Cites] Virchows Arch. 1998 Sep;433(3):237-42 [9769127.001]
  • [Cites] J Gastrointest Surg. 2006 Apr;10(4):511-8 [16627216.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1232-7 [16804874.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Br J Surg. 2007 Mar;94(3):265-73 [17318801.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):181-2 [17667494.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4 Suppl):S81-6 [17916525.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):734-40 [17968163.001]
  • [Cites] BMC Cancer. 2008;8:5 [18194510.001]
  • [Cites] J Clin Gastroenterol. 2002 Aug;35(2):180-4 [12172365.001]
  • (PMID = 19418067.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2848727
  •  go-up   go-down


60. Kodama K, Mizuno T, Imahori T, Ida M, Matsubara F: Concurrent diagnosis of urothelial carcinoma and squamous cell carcinoma of the bladder in a patient with a vesicorectal fistula from invasive rectal cancer. Int J Urol; 2006 Mar;13(3):296-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent diagnosis of urothelial carcinoma and squamous cell carcinoma of the bladder in a patient with a vesicorectal fistula from invasive rectal cancer.
  • A 47-year-old man underwent a low anterior resection of the rectosigmoid colon with en bloc cystoprostatectomy for vesicorectal fistula due to a locally advanced rectal cancer.
  • To our knowledge, this is the first reported case of two histologically distinct urothelial malignancies that were diagnosed during a work up of vesicorectal fistula due to adenocarcinoma of the rectum.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Rectal Fistula / etiology. Rectal Neoplasms / diagnosis. Urinary Bladder Fistula / etiology. Urinary Bladder Neoplasms / diagnosis


61. Ribeiro ML, Priolli DG, Miranda DD, Arçari DP, Pedrazzoli J Jr, Martinez CA: Analysis of oxidative DNA damage in patients with colorectal cancer. Clin Colorectal Cancer; 2008 Jul;7(4):267-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of oxidative DNA damage in patients with colorectal cancer.
  • PURPOSE: The aim of this study was to measure the levels of oxidative DNA damage in cells isolated from the colon mucosa in patients with colorectal cancer and to compare normal and neoplastic tissues and make correlations with anatomopathologic variables.
  • PATIENTS AND METHODS: Thirty-three patients with colorectal adenocarcinoma were studied.
  • The cells isolated from the neoplastic mucosal tissue of the colon presented significantly greater mean extent of DNA strand breakage than the cells isolated from normal tissue.
  • CONCLUSION: Assessment of the levels of oxidative damage at the different stages of colorectal carcinogenesis is of great interest because it enables evaluation of the effectiveness of antioxidant substances that could be used as preventive measures against the initial oxidative aggressive action on the colonic mucosa.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Aged. Antioxidants / therapeutic use. Comet Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Reactive Oxygen Species / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650195.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Reactive Oxygen Species
  •  go-up   go-down


62. Gamblin TC, Santos RS, Baratz M, Landreneau RJ: Metastatic colon cancer to the hand. Am Surg; 2006 Jan;72(1):98-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colon cancer to the hand.
  • A 72-year-old male presented with a painful index finger 18 months after sigmoid colon resection for T2 N1 adenocarcinoma.
  • The patient underwent ray amputation of the involved digit and shortly later resection of a solitary pulmonary nodule consistent with colonic metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Colonic Neoplasms / pathology. Finger Phalanges

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494196.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Morikawa T, Nishimatsu H, Kadono T, Homma Y, Fukayama M: Urinary bladder metastasis from extramammary Paget's disease in a patient with a past history of colon and gastric cancers. Pathol Int; 2010 Feb;60(2):145-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder metastasis from extramammary Paget's disease in a patient with a past history of colon and gastric cancers.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Colonic Neoplasms / pathology. Groin / pathology. Humans. Male. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398202.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  •  go-up   go-down


64. Sánchez-Fructuoso A, Conesa J, Perez Flores I, Ridao N, Calvo N, Prats D, Rodríguez A, Barrientos A: Conversion to sirolimus in renal transplant patients with tumors. Transplant Proc; 2006 Oct;38(8):2451-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This prospective study of 29 patients included 2 patients with skin cancer (1 melanoma and 1 squamous cell carcinoma) and 27 patients who developed other tumors: lung (n = 6), prostate (n = 4), lymphoma (n = 2), colon adenocarcinoma (n = 2), kidney (n = 2), Kaposi sarcoma (n = 2), urothelium (n = 1), parotid (n = 1), larynx (n = 1), gastric (n = 1), breast (n = 1), tongue (n = 1), liver (n = 1), xanthoastrocytoma (n = 1), and aggressive angiomyxoma of the perineum (n = 1).

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097964.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; AYI8EX34EU / Creatinine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


65. Meroni E, Gatteschi B, Fasoli A, Munizzi F, Frascio F, Pugliese V, Truini M: Detection of tissue abnormalities in normal mucosa surrounding colorectal cancer using an endocytoscopy system. Endoscopy; 2007 Apr;39(4):369-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of tissue abnormalities in normal mucosa surrounding colorectal cancer using an endocytoscopy system.
  • In one surgical specimen obtained after resection of a cancer of the transverse colon, focal abnormalities of colonic glands were detected 7 cm away from the primary tumor, within macroscopically normal mucosa.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Endoscopy, Gastrointestinal / methods. Intestinal Mucosa / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427076.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


66. Kanellos I, Zacharakis E, Kanellos D, Pramateftakis MG, Betsis D: Prognostic significance of CEA levels and positive cytology in peritoneal washings in patients with colorectal cancer. Colorectal Dis; 2006 Jun;8(5):436-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CEA levels and positive cytology in peritoneal washings in patients with colorectal cancer.
  • OBJECTIVE: The aims of this prospective study were to determine carcinoembryonic antigen (CEA) levels and incidence of cytology in peritoneal washings of patients with colorectal cancer, correlate the results with various histopathological factors and determine their significance as prognostic factors of the disease.
  • METHODS: From 1992 to 1999, 98 patients with adenocarcinoma of the colon or intraperitoneal rectum underwent curative surgery and enrolled in this study.
  • CONCLUSIONS: The presence of free malignant cells, as detected by cytology and CEA level, in the peritoneal cavity of patients with resectable colorectal cancer had no detectable impact on survival, hepatic metastases or local recurrence rate.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16684089.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


67. Kim SG, Park MY, Kim CH, Sohn HJ, Kim HS, Park JS, Kim HJ, Oh ST, Kim TG: Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Vaccine; 2008 Nov 25;26(50):6433-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoembryonic antigen (CEA) is expressed on human colon carcinomas, is well characterized, and continues to be a promising target for cancer immunotherapy in humans.
  • [MeSH-major] Adenocarcinoma / immunology. Calreticulin. Cancer Vaccines. Carcinoembryonic Antigen. Colonic Neoplasms / immunology. Dendritic Cells / immunology. Gene Products, tat

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812201.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Calreticulin; 0 / Cancer Vaccines; 0 / Carcinoembryonic Antigen; 0 / Gene Products, tat; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


68. Hoshina K, Kobayashi I, Kuwano H, Kurita M, Shida D, Shinkai H, Miyashita M: [A case of metastatic colon cancer to paraaortic lymph nodes and liver treated successfully with oxaliplatin combination chemotherapy]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic colon cancer to paraaortic lymph nodes and liver treated successfully with oxaliplatin combination chemotherapy].
  • A 62-year-old female had been operated for sigmoid colon cancer and liver metastasis.
  • We showed our original guideline of adjuvant chemotherapy for colorectal cancer to the patient.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637557.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


69. Peschaud F, Benoist S, Julié C, Beauchet A, Penna C, Rougier P, Nordlinger B: The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer. Ann Surg; 2008 Dec;248(6):1067-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer.
  • OBJECTIVE: The aim of the study was to evaluate the prognostic value of the ratio of metastatic to examined lymph nodes (LNR) in patients with rectal cancer.
  • SUMMARY BACKGROUND DATA: Lymph nodes ratio (LNR) has been shown to have prognostic value in patients with colon cancer.
  • The impact of LNR on disease-free and overall survival in patients with rectal cancer is unknown.
  • PATIENTS AND METHODS: From 1998 to 2004, 307 patients underwent rectal resection for adenocarcinoma.
  • CONCLUSIONS: LNR is the most significant prognostic factor for both overall and disease-free survival in patients with rectal cancer, even in patients with fewer than 12 lymph nodes examined.
  • [MeSH-major] Adenocarcinoma / pathology. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg. 2009 Apr;249(4):701.. Frederique, Peschaud [corrected to Peschaud, Frederique]; Stephane, Benoist [corrected to Benoist, Stephane]; Catherine, Julié [corrected to Julié, Catherine]; Alain, Beauchet [corrected to Beauchet, Alain]; Christophe, Penna [corrected to Penna, Christophe]; Philippe, Rougier [corrected to Rougier, Philippe]
  • (PMID = 19092352.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP: Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A; 2008 Sep 9;105(36):13427-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity.
  • Colon carcinoma is one of the leading causes of death from cancer and is characterized by a heterogenic pool of cells with distinct differentiation patterns.
  • Recently, it was reported that a population of undifferentiated cells from a primary tumor, so-called cancer stem cells (CSC), can reconstitute the original tumor on xenotransplantation.
  • Here, we show that spheroid cultures of these colon CSCs contain expression of CD133, CD166, CD44, CD29, CD24, Lgr5, and nuclear beta-catenin, which have all been suggested to mark the (cancer) stem cell population.
  • More importantly, by using these spheroid cultures or freshly isolated tumor cells from multiple colon carcinomas, we now provide compelling evidence to indicate that the capacity to propagate a tumor with all differentiated progeny resides in a single CSC.
  • Single-cell-cloned CSCs can form an adenocarcinoma on xenotransplantation but do not generate the stroma within these tumors.
  • These data support the hypothesis that tumor hierarchy can be traced back to a single CSC that contains multilineage differentiation capacity, and provides clues to the regulation of differentiation in colon cancers in vivo.
  • [MeSH-major] Cell Differentiation. Cell Lineage. Cell Separation / methods. Colonic Neoplasms / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Humans. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / metabolism. Protein Kinase Inhibitors / pharmacology. Tissue Culture Techniques

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):150-8 [17306971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8985-8 [17908998.001]
  • [Cites] Gut. 2003 Oct;52(10):1472-8 [12970141.001]
  • [Cites] Cell. 2004 Mar 19;116(6):769-78 [15035980.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):43-7 [15108804.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:270-4 [15153444.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1329-45 [857028.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):343-52 [3335311.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] J Pathol. 1993 Aug;170(4):441-50 [8410493.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):301-6 [7927933.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] Cell Death Differ. 2008 Jun;15(6):947-58 [18259194.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • (PMID = 18765800.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Kinase Inhibitors; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Other-IDs] NLM/ PMC2533206
  •  go-up   go-down


71. Németh E, Halász A, Baráth A, Domokos M, Gálfi P: Effect of hydrogen peroxide on interleukin-8 synthesis and death of Caco-2 cells. Immunopharmacol Immunotoxicol; 2007;29(2):297-310
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the time- and dose-dependent induction of IL-8 by hydrogen peroxide in the human colon adenocarcinoma cell line Caco-2.

  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17849273.001).
  • [ISSN] 0892-3973
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; BBX060AN9V / Hydrogen Peroxide; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


72. Mitrofanova E, Unfer R, Vahanian N, Kane S, Carvour M, Link C: Effective growth arrest of human colon cancer in mice, using rat sodium iodide symporter and radioiodine therapy. Hum Gene Ther; 2005 Nov;16(11):1333-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective growth arrest of human colon cancer in mice, using rat sodium iodide symporter and radioiodine therapy.
  • Rat sodium iodide symporter (rNIS) for radioiodide therapy of cancer. Clin.
  • Cancer Res. 10, 6969-6976].
  • In this work the ability of the rNIS and 131I system to inhibit the growth of relatively large (about 800 mm3 when treated with 131I) and rapidly growing colon tumors in an animal model was examined. in vitro experiments demonstrated that transduction of human colon cancer cells with Ad-rNIS resulted in a 100- to 150-fold increase in 125I uptake compared with nontransduced cells.
  • Western blot analysis revealed robust expression of rNIS protein in cells 72-120 hr posttransduction with Ad-rNIS.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Division. Colorectal Neoplasms / pathology. Iodine Radioisotopes / therapeutic use. Symporters / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259567.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Symporters; 0 / sodium-iodide symporter
  •  go-up   go-down


73. Christie DR, Shaikh FM, Lucas JA 4th, Lucas JA 3rd, Bellis SL: ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res; 2008 Oct 01;1(1):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function.
  • BACKGROUND: Ovarian adenocarcinoma is not generally discovered in patients until there has been widespread intraperitoneal dissemination, which is why ovarian cancer is the deadliest gynecologic malignancy.
  • Our laboratory has previously shown that the Golgi glycosyltransferase, ST6Gal-I, mediates the hypersialylation of beta1 integrins in colon adenocarcinoma, which leads to a more metastatic tumor cell phenotype.
  • Interestingly, ST6Gal-I mRNA is known to be upregulated in metastatic ovarian cancer, therefore the goal of the present study was to determine whether ST6Gal-I confers a similarly aggressive phenotype to ovarian tumor cells.
  • CONCLUSION: ST6Gal-I mediated sialylation of beta1 integrins in ovarian cancer cells may contribute to peritoneal metastasis by altering tumor cell adhesion and migration through extracellular matrix.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(5):436-44 [16319516.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):67-75 [11206841.001]
  • [Cites] Clin Exp Metastasis. 2004;21(8):685-97 [16035613.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4645-52 [15930282.001]
  • [Cites] Glycobiology. 1999 Oct;9(10):1003-8 [10521536.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2253-9 [9605774.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):362-7 [10366461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5722-7 [10318951.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1525-37 [10329605.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):243-7 [10188726.001]
  • [Cites] Oncology. 1999;56(2):89-96 [9949292.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4066-70 [9751611.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(9-10):437-41 [9438113.001]
  • [Cites] Biochim Biophys Acta. 1998 Jan 8;1379(1):23-8 [9468328.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4249-56 [9331085.001]
  • [Cites] FEBS Lett. 1997 Jun 16;409(3):347-50 [9224687.001]
  • [Cites] Int J Cancer. 1996 Sep 17;67(6):826-30 [8824555.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10637-43 [8144653.001]
  • [Cites] Eur J Biochem. 1993 Jan 15;211(1-2):135-40 [7678804.001]
  • [Cites] Glycobiology. 1992 Feb;2(1):49-56 [1550989.001]
  • [Cites] J Biol Chem. 1990 Oct 15;265(29):17849-53 [2211665.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):617-20 [1911209.001]
  • [Cites] Eur J Biochem. 2004 Sep;271(18):3623-34 [15355339.001]
  • [Cites] Biochim Biophys Acta. 2004 May 27;1663(1-2):52-60 [15157607.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7137-45 [14562042.001]
  • [Cites] Hybridoma. 2000 Aug;19(4):281-6 [11001400.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 Jan;3(1):48-52 [10683317.001]
  • [Cites] Glycobiology. 2007 Dec;17(12):1344-56 [17884841.001]
  • [Cites] Lab Invest. 2007 Sep;87(9):851-7 [17632542.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6701-6 [16425369.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):395-401 [12798701.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] Med Res Rev. 2003 Jan;23(1):32-47 [12424752.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32830-6 [12091385.001]
  • [Cites] Exp Cell Res. 2002 May 15;276(1):101-10 [11978012.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2071-80 [11733357.001]
  • [Cites] Biochim Biophys Acta. 2001 May 31;1536(2-3):148-60 [11406350.001]
  • [Cites] Glycoconj J. 2000 Oct;17(10):669-76 [11425186.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):631-9 [16112178.001]
  • (PMID = 19014651.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA084248
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2584051
  •  go-up   go-down


74. Prall F, Ostwald C, Schiffmann L, Barten M: Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? Oncol Rep; 2007 Jul;18(1):203-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
  • Since 5-fluorouracil (5-FU)-based chemotherapy has become standard adjuvant treatment for patients with node-positive colonic adenocarcinoma, there has arisen the need for predictive factors.
  • All patients with a single, non-metachronous node-positive colonic adenocarcinoma who underwent a potentially curative resection at this institution in the years 1994-2002, and who received adjuvant 5-FU (n=95) were included in this study.
  • These results argue against a practical role for the TS gene repeat polymorphism or the C/G single nucleotide polymorphism as a predictive factor.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Fluorouracil / therapeutic use. Polymorphism, Single Nucleotide. Promoter Regions, Genetic / genetics. Thymidylate Synthase / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Disease Progression. Drug Resistance, Neoplasm. Female. Genotype. Humans. Male. Middle Aged. Polymerase Chain Reaction. Retrospective Studies. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549369.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


75. Griniatsos J, Michail OP, Theocharis S, Arvelakis A, Papaconstantinou I, Felekouras E, Pikoulis E, Karavokyros I, Bakoyiannis C, Marinos G, Bramis J, Michail PO: Circadian variation in expression of G1 phase cyclins D1 and E and cyclin-dependent kinase inhibitors p16 and p21 in human bowel mucosa. World J Gastroenterol; 2006 Apr 7;12(13):2109-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between January 2003 and December 2004, twenty patients who were diagnosed as suffering from primary, resectable, non-metastatic adenocarcinoma of the lower rectum, infiltrating the sphincter mechanism, underwent abdominoperineal resection, total mesorectal excision and permanent left iliac colostomy.
  • In formalin-fixed and paraffin-embedded biopsy specimens obtained from the colostomy mucosa every six hours (00:00, 06:00, 12:00, 18:00 and 24:00), we studied the expression of G(1) phase cyclins (D(1) and E) as well as the expression of the G(1) phase cyclin-dependent kinase (CDK) inhibitors p16 and p21 as indicators of cell cycle progression in colonic epithelial cells using immunohistochemical methods.
  • CONCLUSION: Colonic epithelial cells seem to enter the G(1) phase of the cell cycle during afternoon (between 12:00 and 18:00) with the highest rates obtained at 18:00.
  • [MeSH-major] Circadian Rhythm. Colon / chemistry. Cyclin D1 / analysis. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. G1 Phase. Intestinal Mucosa / chemistry

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1997 Apr 1;11(7):847-62 [9106657.001]
  • [Cites] Nat Med. 1997 Feb;3(2):222-5 [9018243.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1238-43 [9529014.001]
  • [Cites] J Korean Med Sci. 1998 Oct;13(5):513-8 [9811181.001]
  • [Cites] Cell. 1999 Jan 22;96(2):271-90 [9988221.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):613-22 [10027418.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1101-5 [10613343.001]
  • [Cites] Cell Res. 2000 Mar;10(1):1-16 [10765979.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):929-42 [11040180.001]
  • [Cites] J Cell Sci. 2001 May;114(Pt 10):1811-20 [11329367.001]
  • [Cites] J Surg Res. 2001 Jun 1;98(1):4-8 [11368530.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):222-31 [11902577.001]
  • [Cites] Chronobiol Int. 2002 Jan;19(1):129-40 [11962671.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):73-87 [11960696.001]
  • [Cites] Pathol Biol (Paris). 2003 Jun;51(4):197-200 [12852987.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):881-2; author reply 882-3 [12910534.001]
  • [Cites] World J Gastroenterol. 2003 Oct;9(10):2202-6 [14562378.001]
  • [Cites] Biomed Pharmacother. 2003 Oct;57 Suppl 1:92s-95s [14572683.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):1756-60 [14696398.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):27-36 [14700606.001]
  • [Cites] Cancer Lett. 2004 May 28;208(2):193-6 [15142678.001]
  • [Cites] Anat Rec. 1978 Aug;191(4):479-86 [697058.001]
  • [Cites] Cell Tissue Kinet. 1981 Mar;14(2):111-20 [6451296.001]
  • [Cites] Am J Anat. 1983 Dec;168(4):433-65 [6320626.001]
  • [Cites] Science. 1989 Nov 3;246(4930):603-8 [2683075.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):410-5 [2065918.001]
  • [Cites] Annu Rev Physiol. 1993;55:16-54 [8466172.001]
  • [Cites] Genes Dev. 1993 May;7(5):812-21 [8491378.001]
  • [Cites] Cell. 1993 Jun 18;73(6):1059-65 [8513492.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1403-17 [8315438.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):704-7 [8259215.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):982-7 [8144003.001]
  • [Cites] Nature. 1994 Apr 21;368(6473):753-6 [8152487.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5291-5 [8202483.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3389-96 [7936667.001]
  • [Cites] Cell. 1994 Nov 18;79(4):573-82 [7954824.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11045-9 [7972006.001]
  • [Cites] Science. 1995 Jan 13;267(5195):249-52 [7809631.001]
  • [Cites] J Cell Sci Suppl. 1994;18:69-73 [7883795.001]
  • [Cites] Cytogenet Cell Genet. 1995;69(3-4):190-2 [7698009.001]
  • [Cites] Mol Cell Biol. 1995 May;15(5):2612-24 [7739542.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4215-24 [7623816.001]
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):617-21 [7559076.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):27374-9 [7593001.001]
  • [Cites] J Cancer Res Clin Oncol. 1996;122(2):122-6 [8576279.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):669-74 [8608874.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:261-91 [9442875.001]
  • (PMID = 16610066.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC4087694
  •  go-up   go-down


76. Higuchi Y, Serizawa T, Nagano O, Matsuda S, Ono J, Sato M, Iwadate Y, Saeki N: Three-staged stereotactic radiotherapy without whole brain irradiation for large metastatic brain tumors. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1543-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary tumors were in the colon in 14 patients, lung in 12, breast in 11, and other in 6.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Colonic Neoplasms / pathology. Disease-Free Survival. Female. Humans. Kidney Neoplasms / pathology. Lung Neoplasms / pathology. Male. Middle Aged. Remission Induction. Survival Rate. Tumor Burden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135317.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Wu SD, Rios RR, Meeks JJ, Nadler RB: Rectal Hem-o-Lok clip migration after robot-assisted laparoscopic radical prostatectomy. Can J Urol; 2009 Dec;16(6):4939-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 61-year-old male with a prostate specific antigen level of 4.84 ng/ml underwent transrectal ultrasound guided biopsy of the prostate revealing a Gleason's 3 + 3 adenocarcinoma of the prostate involving 20% of the sampled tissue for the left apex.
  • RESULTS: Final pathology demonstrated a Gleason 4 + 3 pT2cN0Mx adenocarcinoma of the prostate with negative margins.
  • This was found on colonoscopy performed for diverticular disease of the colon.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Colonoscopy / methods. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20003674.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


78. Ebert MP, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L, Hoffmann J, Csepregi A, Röcken C, Molnar B, Schulz HU, Malfertheiner P, Lofton-Day C: Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology; 2006 Nov;131(5):1418-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.
  • BACKGROUND & AIMS: The identification of novel genetic and epigenetic markers indicative of changes in the pathogenesis of colon cancer, along with easier-to-use, more sensitive assay methods, may improve the detection, treatment, and overall prognosis of this malignancy.
  • METHODS: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified.
  • Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma.
  • ALX4 methylation was also analyzed in the serum of 30 patients with colon cancer.
  • RESULTS: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P < .0001).
  • In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P < .001).
  • ALX4 gene methylation was also more frequently found in sera of patients with colon cancer compared with noncancer controls (P < .0001).
  • CONCLUSIONS: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract.
  • ALX4 gene methylation in sera of patients with cancer may thus serve as a methylation-specific test for colon and other gastrointestinal cancers.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. DNA-Binding Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Colonic Polyps / genetics. DNA Methylation. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Metastasis. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101318.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALX4 protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors
  •  go-up   go-down


79. Kim JH, Cheon JH, Kim TI, Baik SH, Kim NK, Kim H, Kim WH: Effectiveness of radical surgery after incomplete endoscopic mucosal resection for early colorectal cancers: a clinical study investigating risk factors of residual cancer. Dig Dis Sci; 2008 Nov;53(11):2941-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of radical surgery after incomplete endoscopic mucosal resection for early colorectal cancers: a clinical study investigating risk factors of residual cancer.
  • The aim of this study was to determine the need for additional treatment following endoscopic mucosal resection for early colorectal cancer.
  • However, after curative surgery, residual cancer within colorectal tissue was found in only five cases (11.4%), while lymph node metastases were found in three cases (6.8%).
  • Gross incomplete resection (P < 0.001) and microscopic vertical margin positivity (P = 0.031) were found to be risk factors of residual cancer within the colorectal tissue, whereas lymphovascular invasion was a risk factor for lymph node metastasis (P = 0.040).
  • However, no residual cancer cells were found after supplementary surgery in the microscopic lateral resection margin-positive cases.
  • In conclusion, grossly incomplete resection, microscopic vertical resection margin positivity, or the presence of lymphovascular invasion after endoscopic mucosal resection for early colorectal cancer indicate the need for further treatment with surgical resection and lymph node dissection.
  • However, microscopic lateral margin positivity without gross remnant tumor and deep submucosal invasion might not indicate residual cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colorectal Neoplasms / surgery. Endoscopy, Gastrointestinal. Neoplasm, Residual / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):48-54 [16377315.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jan;19(1):48-55 [14675242.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3053-63 [11095318.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):323-8 [1848810.001]
  • [Cites] Gastric Cancer. 2005;8(3):149-54 [16086117.001]
  • [Cites] Dig Dis Sci. 2007 Mar;52(3):840-4 [17253129.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1658-61 [15532798.001]
  • [Cites] Hepatogastroenterology. 2004 Jul-Aug;51(58):998-1000 [15239233.001]
  • [Cites] J Gastroenterol. 2004 Jun;39(6):534-43 [15235870.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s283-90 [15666108.001]
  • [Cites] Dis Colon Rectum. 2007 Sep;50(9):1370-6 [17661146.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):759-67 [11895906.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):371-5 [11868011.001]
  • [Cites] Dig Liver Dis. 2007 Jun;39(6):566-71 [17382610.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):2-8 [14631370.001]
  • [Cites] Am J Surg Pathol. 1983 Oct;7(7):613-23 [6638257.001]
  • [Cites] Am J Gastroenterol. 1994 Mar;89(3):334-8 [8122640.001]
  • [Cites] Gastroenterology. 1995 Dec;109(6):1801-7 [7498644.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):212-8 [16860071.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Oct;18(10):1175-9 [12974905.001]
  • (PMID = 18357528.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Guillem JG, Chessin DB, Shia J, Suriawinata A, Riedel E, Moore HG, Minsky BD, Wong WD: A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation. Ann Surg; 2007 Jan;245(1):88-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation.
  • OBJECTIVE: The aims of this study were to use a comprehensive whole-mount pathologic analysis to characterize microscopic patterns of residual disease, as well as circumferential and distal resection margins, in rectal cancer treated with preoperative CMT; and to identify clinicopathologic factors associated with residual disease.
  • SUMMARY BACKGROUND DATA: Recent studies have shown that preoperative combined modality therapy (CMT) for rectal cancer enhances rates of sphincter preservation.
  • METHODS: We prospectively accrued 109 patients with endorectal ultrasound (ERUS)-staged, locally advanced rectal cancer (T2-T4 and/or N1), located a median distance of 7 cm from the anal verge, requiring preoperative CMT, and undergoing a TME-based resection.
  • CONCLUSION: Our comprehensive pathologic analysis suggests that, following preoperative CMT and a TME-based resection, distal margins of 1 cm may provide for complete removal of locally advanced rectal cancer.
  • Although residual cancer following preoperative CMT was more likely in the setting of distally located tumors, occult tumor beneath the mucosal edge was rare and, when present, limited to less than 1 cm.
  • Our results extend the indications for sphincter preservation, as distal resection margins of only 1 cm may be acceptable for rectal cancer treated with preoperative CMT.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2005 Mar;241(3):465-9 [15729069.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):979-83 [9715152.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3475-9 [15908656.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):18-24 [10813118.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):163-9 [11258782.001]
  • [Cites] Ann Surg Oncol. 2001 Aug;8(7):611-5 [11508624.001]
  • [Cites] Br J Surg. 2002 Mar;89(3):327-34 [11872058.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):75-81 [12131088.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):48-58 [14719151.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):80-5 [12513965.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • [Cites] J R Soc Med. 1987 Jan;80(1):23-4 [3550076.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]
  • [Cites] J Am Coll Surg. 1995 Oct;181(4):335-46 [7551328.001]
  • [Cites] Cancer. 1995 Aug 1;76(3):388-92 [8625118.001]
  • [Cites] Br J Surg. 1996 Jun;83(6):781-5 [8696739.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):969-72 [8813789.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):25-9 [9102256.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Ann Surg. 2005 May;241(5):829-36; discussion 836-8 [15849519.001]
  • (PMID = 17197970.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / R01 82534-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1867929
  •  go-up   go-down


81. Henderson-Jackson EB, Helm J, Ghayouri M, Hakam A, Nasir A, Leon M, Bui M, Yeatman T, Coppola D: Correlation between Mcl-1 and pAKT protein expression in colorectal cancer. Int J Clin Exp Pathol; 2010;3(8):768-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between Mcl-1 and pAKT protein expression in colorectal cancer.
  • Expression of pAKT and Mcl-1 have been described in colon cancer, however, the relationship between pAKT and Mcl-1 has not.
  • Mcl-1 and pAKT immunohistochemistry was performed using colorectal cancer tissue microarray (TMA).
  • Mcl-1 and pAKT scores were compared for normal colorectal mucosa (NR), adenoma (AD), and colorectal cancer (CRC) cohorts.
  • The mean (SD) pAKT expression in NR (14) was 2.0 (1.4), in AD (8) was 3.0 (1.7), and in CRC (101) was 5.6 (2.4).
  • For Mcl-1 the mean (SD) expression was 4.1 (1.7) in NR, 3.2 (1.2) in AD, and 3.3 (2.6) in CRC.
  • Mcl-1 and pAKT scores were directly correlated during various stages of colon car-cinogenesis (p = 0.04).
  • We report the correlation of Mcl-1 protein expression with higher grade and stage in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism


82. Noorani S, Rao AR, Callaghan PS: Urethral metastasis: an uncommon presentation of a colonic adenocarcinoma. Int Urol Nephrol; 2007;39(3):837-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urethral metastasis: an uncommon presentation of a colonic adenocarcinoma.
  • In this report, however we describe a case of urethral metastases from a colonic cancer origin where the urethral lesion was the presenting symptom.
  • Excision biopsy revealed adenocarcinoma.
  • Immunohistochemical staining demonstrated that the tumour cells were strongly suggestive of a metastatic lesion from the colon.
  • Subsequent investigations revealed that the patient did indeed have a sigmoid adenocarcinoma and underwent chemotherapy with a view to anterior resection and pelvic exenteration.
  • [MeSH-major] Adenocarcinoma / secondary. Sigmoid Neoplasms / pathology. Urethral Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Apr;163(4):1245-6 [10737510.001]
  • [Cites] Arch Pathol Lab Med. 2002 Sep;126(9):1057-63 [12204054.001]
  • [Cites] ANZ J Surg. 2004 Oct;74(10):925-7 [15456455.001]
  • [Cites] Arch Surg. 1973 Dec;107(6):906-8 [4751838.001]
  • [Cites] Int Braz J Urol. 2003 Sep-Oct;29(5):431-3 [15745589.001]
  • [Cites] Indian J Cancer. 1994 Mar;31(1):31-3 [8063334.001]
  • (PMID = 17318345.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


83. Goldstein NS: Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am J Clin Pathol; 2006 Jan;125(1):132-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases.
  • Eight sessile serrated adenoma (SSA), right colon polypectomies with focal invasive adenocarcinoma or high-grade dysplasia were studied to identify features indicating a high risk of transformation and characterize the morphologic features of serrated dysplasia; 6 cases had invasive adenocarcinoma; 2 were high-grade dysplasia.
  • In the 6 invasive adenocarcinomas, the neoplasm extended directly down into the submucosa without lateral intramucosal spread.
  • The mean maximum dimension of the invasive adenocarcinoma was 2.9 mm (range, 2-4 mm).
  • Small proximal SSAs can transform into adenocarcinoma without a component of adenomatous dysplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Chromosomal Instability. Colonic Neoplasms / pathology. Microsatellite Repeats
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Aged. Aged, 80 and over. Carrier Proteins / analysis. Cell Transformation, Neoplastic / pathology. Colonic Polyps / pathology. Epithelium / pathology. Humans. Middle Aged. Nuclear Proteins / analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483002.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


84. Allardyce RA, Bagshaw PF, Frampton CM, Frizelle FA, Hewett PJ, Rieger NA, Smith S, Solomon MJ, Stevenson AR: Australian and New Zealand study comparing laparoscopic and open surgeries for colon cancer in adults: organization and conduct. ANZ J Surg; 2008 Oct;78(10):840-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Australian and New Zealand study comparing laparoscopic and open surgeries for colon cancer in adults: organization and conduct.
  • This article describes the initiation and implementation of the multicentre Australia and New Zealand prospective randomized controlled clinical study comparing laparoscopic and conventional open surgical treatments of right-sided and left-sided potentially curable colon cancer (Australasian Laparoscopic Colon Cancer Study).
  • Six hundred and one adult patients were admitted with a clinical diagnosis of a single adenocarcinoma based on a physical examination and colonoscopy, barium enema or computed tomography scan and randomly allocated to either laparoscopic or open surgery.
  • The Australasian Laparoscopic Colon Cancer Study will achieve its aims with 5-year assessments of all entered patients in March 2010.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18959634.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


85. Friedrich M, Diesing D, Cordes T, Fischer D, Becker S, Chen TC, Flanagan JN, Tangpricha V, Gherson I, Holick MF, Reichrath J: Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res; 2006 Jul-Aug;26(4A):2615-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The presence of extra-renal 25-hydroxyvitamin D3 [25(OH)D3]-1alpha-hydroxylase (1alpha-OHase) has been reported in several cell types including prostate and colon cancer cells.
  • The aim of this study was to analyze whether normal breast tissue or breast cancer cells expressed 1alpha-OHase and to evaluate whether breast tissue possessed the capacity to produce 1alpha,25(OH)2D3 from 25(OH)D3.
  • MATERIALS AND METHODS: Total RNA was extracted from normal breast tissue (n = 11), breast carcinomas (n = 12) and cultured MCF-7 breast cancer cells for real-time (LightCycler using specific hybridization probes) and conventional PCR analysis.
  • RESULTS: mRNA for 1alpha-OHase was detected in breast cancer tissue and in MCF-7 breast cancer cells.
  • Interestingly, the mRNA levels for 1alpha-OHase were significantly increased in breast cancer compared to normal breast tissue.
  • CONCLUSION: The data suggest that at least breast cancer cells expressed 1alpha-OHase mRNA and, therefore, might have the ability to synthesize 1alpha,25(OH)2D3 within the cells.
  • We hypothesize that alterations in the local production of 1alpha,25(OH)2D3 may be involved in the tumorigenesis of breast cancer.
  • Additionally, breast cancer may be a target for treatment with precursors of biologically-active vitamin D analogs.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast / cytology. Breast / enzymology. Breast / metabolism. Calcifediol / metabolism. Calcitriol / biosynthesis. Cell Growth Processes / physiology. Cell Line, Tumor. Female. Humans. Polymerase Chain Reaction. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886671.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.14.- / 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; FXC9231JVH / Calcitriol; P6YZ13C99Q / Calcifediol
  •  go-up   go-down


86. Tsujino M, Fujii M, Okabe K, Mori T, Fukushima N, Tsujiuchi T: Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells. Virchows Arch; 2010 Dec;457(6):669-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells.
  • In this study, we examined the expression profiles and DNA methylation status of LPA receptor 1-5 (LPA1-5) genes in human colon cancer cells and also looked for the mutations.
  • On the basis of the present results, we demonstrate that these colon cancer cells will be available to understanding the molecular pathway through LPA receptors in the development of tumor cells, and that LPA receptors may be new molecular targets for therapeutic approaches and chemoprevention.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. DNA Methylation / physiology. DNA, Neoplasm / physiology. Receptors, Lysophosphatidic Acid / genetics. Receptors, Lysophosphatidic Acid / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2008 Mar;40(3):335-9 [18297072.001]
  • [Cites] Lab Invest. 2004 Oct;84(10):1352-62 [15220934.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jan 16;378(3):424-7 [19026987.001]
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23589-97 [16774927.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13384-9 [11087877.001]
  • [Cites] Mol Pharmacol. 2000 Dec;58(6):1188-96 [11093753.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5370-5 [10537322.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25600-6 [12724320.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5358-60 [12154398.001]
  • [Cites] J Biol Chem. 1999 Sep 24;274(39):27776-85 [10488122.001]
  • [Cites] Biochim Biophys Acta. 2008 May;1783(5):748-59 [18157949.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4308-18 [10632375.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92 (2):249-56 [11291053.001]
  • [Cites] Mutat Res. 2009 Jan 15;660(1-2):47-50 [19000703.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1706-11 [12670925.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(19):6921-9 [12215548.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):329-34 [18297070.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2010 Apr;91(3-4):130-8 [20331961.001]
  • [Cites] Carcinogenesis. 1997 May;18(5):869-82 [9163670.001]
  • [Cites] J Toxicol Pathol. 2010 Mar;23(1):63-6 [22272013.001]
  • [Cites] J Biol Chem. 1998 Apr 3;273(14):7906-10 [9525886.001]
  • [Cites] Cancer Lett. 2003 Mar 31;192(2):161-9 [12668280.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Oct 27;349(3):1151-5 [16970915.001]
  • (PMID = 20890765.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / LPAR5 protein, human; 0 / P2RY9 receptor, human; 0 / Receptors, Lysophosphatidic Acid; 0 / Receptors, Purinergic
  •  go-up   go-down


87. Kanellos I, Zacharakis E, Kanellos D, Pramateftakis MG, Tsahalis T, Altsitsiadis E, Betsis D: Prognostic significance of CEA levels and detection of CEA mRNA in draining venous blood in patients with colorectal cancer. J Surg Oncol; 2006 Jul 1;94(1):3-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CEA levels and detection of CEA mRNA in draining venous blood in patients with colorectal cancer.
  • BACKGROUND AND OBJECTIVES: The aims of this study were to determine carcinoembryonic antigen (CEA) levels and incidence of tumor cells using the RT-PCR technique in draining venous blood of patients with colorectal cancer, correlate the results with various histopathologic factors and determine their significance as prognostic factors.
  • METHODS: From 1995 to 2000, 108 patients with adenocarcinoma of the colon or rectum, underwent curative surgery and enrolled in this prospective study.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Carcinoembryonic Antigen / genetics. Colonic Neoplasms / diagnosis. Rectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788936.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / RNA, Messenger
  •  go-up   go-down


88. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G: Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer; 2007 Apr 10;96(7):1118-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.
  • In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up.
  • Our findings suggest that fascin is a useful prognostic marker for colonic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):593-600 [8579121.001]
  • [Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5443-53 [10026156.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] J Cell Biol. 1986 Aug;103(2):631-40 [3525578.001]
  • [Cites] Cell Struct Funct. 1988 Oct;13(5):373-85 [3224379.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):93-101 [15572091.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4 [16360006.001]
  • [Cites] Clin Colorectal Cancer. 2006 May;6(1):38-45 [16796790.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42 [16870459.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6 [14571738.001]
  • [Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]
  • (PMID = 17375048.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC2360113
  •  go-up   go-down


89. Bilimoria KY, Bentrem DJ, Nelson H, Stryker SJ, Stewart AK, Soper NJ, Russell TR, Ko CY: Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States. Arch Surg; 2008 Sep;143(9):832-9; discussion 839-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States.
  • BACKGROUND: Laparoscopic-assisted colectomy (LAC) has gained acceptance for the treatment of colon cancer.
  • SETTING: National Cancer Data Base.
  • PATIENTS: Patients who underwent LAC (n = 11 038) and OC (n = 231 381) for nonmetastatic colon cancer (1998-2002).
  • Patients were significantly more likely to undergo LAC if they were younger than 75 years, had private insurance, lived in higher-income areas, had stage I cancer, had descending and/or sigmoid cancers, or were treated at National Cancer Institute-designated hospitals.
  • After adjusting for patient, tumor, treatment, and hospital factors, 5-year survival was significantly better after LAC compared with OC for stage I and II but not for stage III cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy. Outcome Assessment (Health Care)

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2009 Mar;144(3):290-1; author reply 291 [19289674.001]
  • (PMID = 18794419.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Shaw A, Reddy MS, Yeung J, Semeraro D, Lund JN, Tierney GM: Barium enema: diagnosis and an unusual discovery. Multiple tablets of Adalat LA 30. Gut; 2008 Jun;57(6):827, 849
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Colon / radiography. Foreign Bodies / radiography. Nifedipine
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / radiography. Aged. Barium Sulfate. Calcium Channel Blockers. Colonic Neoplasms / complications. Colonic Neoplasms / radiography. Contrast Media. Enema. Female. Humans. Intestinal Obstruction / complications. Tablets

  • MedlinePlus Health Information. consumer health - Foreign Bodies.
  • Hazardous Substances Data Bank. Nifedipine .
  • Hazardous Substances Data Bank. Barium sulfate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477682.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Contrast Media; 0 / Tablets; 25BB7EKE2E / Barium Sulfate; I9ZF7L6G2L / Nifedipine
  •  go-up   go-down


91. Meng XN, Jin Y, Yu Y, Bai J, Liu GY, Zhu J, Zhao YZ, Wang Z, Chen F, Lee KY, Fu SB: Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer; 2009 Jul 21;101(2):327-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion.
  • BACKGROUND: Focal adhesion kinase (FAK) is overexpressed in a variety of cancers, such as breast, colon, prostate, ovary, and lung cancers.
  • However, the mechanism by which extracellular matrix fibronectin stimulates lung cancer cell migration and invasion through FAK remains to be investigated.
  • METHODS: The signalling pathways in fibronectin-mediated lung cancer cell migration and invasion were examined using western blotting.
  • RESULTS: In this study, we examined the FAK signalling pathways in relation to calpain-2 and RhoA in fibronectin-mediated lung cancer cell migration and invasion.
  • CONCLUSION: Our data suggest that fibronectin-mediated activation of FAK that leads to lung cancer metastasis could occur through ERK or PI3K/Akt regulation of MMP9/calpain-2 or MMP9/RhoA activity, respectively.
  • [MeSH-major] Adenocarcinoma / metabolism. Fibronectins / metabolism. Focal Adhesion Kinase 1 / metabolism. Lung Neoplasms / metabolism


92. Das P, Jain D, Vaiphei K, Wig JD: Abberant crypt foci -- importance in colorectal carcinogenesis and expression of p53 and mdm2: a changing concept. Dig Dis Sci; 2008 Aug;53(8):2183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Till date, in human ACF, K-ras, beta-catenin, carcinoembryonic antigen (CEA) and adenomatous polyposis coli (APC) protein expression have been investigated, but the expression of late markers of colon carcinogenesis have not been studied in great detail.
  • [MeSH-major] Adenocarcinoma / chemistry. Cell Transformation, Neoplastic / chemistry. Colorectal Neoplasms / chemistry. Precancerous Conditions / chemistry. Proto-Oncogene Proteins c-mdm2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1998 Dec 24;17(25):3287-99 [9916991.001]
  • [Cites] Cancer Sci. 2004 Oct;95(10):792-7 [15504245.001]
  • [Cites] Carcinogenesis. 1999 Jun;20(6):1005-9 [10357780.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):63-6 [9892186.001]
  • [Cites] Mol Med. 1999 Feb;5(2):71-83 [10203572.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1153-9 [16474178.001]
  • [Cites] Asian Pac J Cancer Prev. 2004 Apr-Jun;5(2):126-32 [15244513.001]
  • [Cites] Hum Pathol. 1991 Mar;22(3):287-94 [1706308.001]
  • [Cites] Chem Biol Interact. 2005 Jun 30;155(1-2):1-9 [15904905.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:1-5 [10466753.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4743-6 [7585496.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1767-72 [8622897.001]
  • [Cites] BMC Cancer. 2003 Nov 06;3:29 [14604438.001]
  • [Cites] Colorectal Dis. 2002 Mar;4(2):76-89 [12780627.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3323-7 [10910031.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Jpn J Cancer Res. 1994 Jul;85(7):692-8 [7915263.001]
  • [Cites] Nutr Cancer. 2002;43(1):1-21 [12467130.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):350-5 [15536336.001]
  • [Cites] Cancer Surv. 1989;8(1):189-200 [2680070.001]
  • [Cites] Pathologe. 2003 Feb;24(1):44-8 [12601477.001]
  • [Cites] Int J Mol Med. 2002 Apr;9(4):353-8 [11891526.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1283-9 [15929758.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1527-33 [7889486.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):271-8 [15765447.001]
  • [Cites] Cytobios. 1993;73(293):73-88 [8319499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15095-100 [12415112.001]
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):352-6 [11819789.001]
  • [Cites] Cancer Lett. 1987 Oct 30;37(2):147-51 [3677050.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2388-92 [12750256.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1050-5 [8892589.001]
  • (PMID = 18080767.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.3.2.27 / MDM2 protein, human; EC 2.3.2.27 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


93. Reyes-Reyes ME, George MD, Roberts JD, Akiyama SK: P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin. Exp Cell Res; 2006 Dec 10;312(20):4056-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin.
  • During hematogenous cancer metastasis, tumor cells separate from a primary mass, enter the bloodstream, disperse throughout the body, migrate across vessel walls, and generate distant colonies.
  • Some cancer cells express P-selectin ligands and attach to immobilized P-selectin, suggesting that these cells can arrest in blood vessels using sequential selectin- and integrin-mediated adhesion, as do leukocytes.
  • Using a model system of cultured Colo 320 human colon adenocarcinoma cells incubated with soluble P-selectin-IgG chimeric protein, we have found that P-selectin can stimulate activation of the alpha(5)beta(1) integrin resulting in a specific increase of adhesion and spreading of these cells on fibronectin substrates.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):701-7 [14760093.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2743-50 [15087389.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17897-904 [14973141.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 May;50(2):87-100 [15157658.001]
  • [Cites] Mol Cells. 2004 Apr 30;17(2):188-202 [15179030.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 30;320(3):773-80 [15240115.001]
  • [Cites] Pancreas. 2005 Oct;31(3):263-74 [16163059.001]
  • [Cites] Cell Cycle. 2005 Sep;4(9):1189-92 [16103752.001]
  • [Cites] Curr Top Med Chem. 2005;5(10):921-8 [16178737.001]
  • [Cites] Breast Cancer Res Treat. 2005 Sep;93(2):159-68 [16187236.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):8-16 [16450376.001]
  • [Cites] Clin Exp Metastasis. 1999 Jul;17(5):377-87 [10651304.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):1956-69 [10688643.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11284-90 [10753939.001]
  • [Cites] J Immunol. 2000 Apr 15;164(8):4348-58 [10754335.001]
  • [Cites] FASEB J. 2000 Aug;14(11):1629-40 [10928998.001]
  • [Cites] Exp Cell Res. 2001 Feb 1;263(1):65-76 [11161706.001]
  • [Cites] Nat Immunol. 2001 Jan;2(1):29-36 [11135575.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 8):1579-89 [11282033.001]
  • [Cites] FEBS Lett. 2001 Jun 15;499(1-2):176-81 [11418135.001]
  • [Cites] APMIS. 2001 Apr;109(4):241-62 [11469496.001]
  • [Cites] Thromb Haemost. 2001 Jul;86(1):316-23 [11487020.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33762-72 [11448946.001]
  • [Cites] Cell Tissue Res. 2001 Sep;305(3):285-98 [11572082.001]
  • [Cites] J Cell Physiol. 2001 Oct;189(1):1-13 [11573199.001]
  • [Cites] EMBO J. 2001 Nov 15;20(22):6327-36 [11707404.001]
  • [Cites] Oncogene. 2001 Dec 6;20(56):8066-74 [11781819.001]
  • [Cites] Mol Endocrinol. 2002 Mar;16(3):552-62 [11875115.001]
  • [Cites] J Clin Invest. 2002 Apr;109(7):863-7 [11927612.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):E65-8 [11944032.001]
  • [Cites] J Cell Biol. 2002 Sep 2;158(5):833-9 [12213832.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] Bioessays. 2002 Oct;24(10):885-93 [12325121.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] J Biol Chem. 2003 Mar 21;278(12):10556-61 [12522146.001]
  • [Cites] J Clin Invest. 2003 Mar;111(6):833-41 [12639989.001]
  • [Cites] Dev Cell. 2003 Aug;5(2):257-71 [12919677.001]
  • [Cites] Circ Res. 2003 Nov 28;93(11):1026-8 [14593000.001]
  • [Cites] Biophys J. 2004 Jan;86(1 Pt 1):544-54 [14695299.001]
  • [Cites] Gut. 1992 Mar;33(3):342-6 [1568652.001]
  • [Cites] Cancer Metastasis Rev. 1992 Nov;11(3-4):227-35 [1423815.001]
  • [Cites] Cell. 1996 Aug 23;86(4):643-53 [8752218.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1661-73 [8909255.001]
  • [Cites] Cell Growth Differ. 1997 Jan;8(1):83-90 [8993837.001]
  • [Cites] Int J Cancer. 1997 Jan 17;70(2):201-7 [9009161.001]
  • [Cites] J Immunol. 1997 Feb 1;158(3):1061-7 [9013943.001]
  • [Cites] Surgery. 2004 Aug;136(2):143-9 [15300173.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):40807-18 [15272025.001]
  • [Cites] Ann N Y Acad Sci. 1981;370:101-18 [6943955.001]
  • [Cites] Thromb Res. 1982 Jul 1;27(1):1-14 [6812233.001]
  • [Cites] J Biol Chem. 1985 Apr 10;260(7):4492-500 [3920218.001]
  • [Cites] J Cell Biol. 1986 Feb;102(2):442-8 [2935540.001]
  • [Cites] J Cell Biol. 1989 Aug;109(2):863-75 [2527241.001]
  • [Cites] Nature. 1989 Dec 14;342(6251):811-3 [2574829.001]
  • [Cites] J Pathol. 1990 Jan;160(1):35-40 [2179505.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1132-5 [1701275.001]
  • [Cites] Am J Pathol. 1991 Mar;138(3):741-50 [2000944.001]
  • [Cites] J Biol Chem. 1991 Apr 25;266(12):7345-52 [1902217.001]
  • [Cites] J Exp Med. 1991 Jun 1;173(6):1493-500 [1709677.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):324-30 [1371572.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Feb 14;182(3):1376-82 [1371681.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2292-6 [1372439.001]
  • [Cites] Eur J Immunol. 1998 Feb;28(2):433-43 [9521050.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2069-75 [9649116.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):836-42 [9670961.001]
  • [Cites] Biochemistry. 1998 Jul 21;37(29):10514-21 [9671523.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30 [9689079.001]
  • [Cites] FASEB J. 1998 Sep;12(12):1241-51 [9737727.001]
  • [Cites] Biochim Biophys Acta. 1998 Dec 8;1436(1-2):127-50 [9838078.001]
  • [Cites] Physiol Rev. 1999 Jan;79(1):181-213 [9922371.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2850-7 [10072533.001]
  • [Cites] Science. 1999 Aug 13;285(5430):1028-32 [10446041.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):339-47 [15668738.001]
  • [Cites] Curr Opin Cell Biol. 2005 Apr;17(2):141-9 [15780590.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2218-28 [15688026.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):354-61 [7678075.001]
  • [Cites] Eur J Surg Oncol. 1993 Feb;19(1):50-60 [8436241.001]
  • [Cites] J Cell Biol. 1993 Apr;121(2):449-59 [7682218.001]
  • [Cites] Int J Cancer. 1993 Jul 30;54(6):972-7 [7687590.001]
  • [Cites] J Clin Invest. 1993 Aug;92(2):804-13 [7688763.001]
  • [Cites] J Biol Chem. 1993 Oct 15;268(29):21459-62 [7691809.001]
  • [Cites] Semin Cancer Biol. 1993 Oct;4(5):319-24 [7903054.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1179-86 [7505206.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):1425-31 [7507108.001]
  • [Cites] Cell. 1994 Jan 28;76(2):301-14 [7507411.001]
  • [Cites] Anticancer Res. 1993 Nov-Dec;13(6A):2229-37 [8297138.001]
  • [Cites] J Cell Biol. 1994 Sep;126(5):1287-98 [8063864.001]
  • [Cites] J Immunol. 1994 Oct 1;153(7):3199-209 [7522253.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8767-71 [7522321.001]
  • [Cites] Clin Exp Metastasis. 1994 Nov;12(6):357-67 [7923988.001]
  • [Cites] Int Immunol. 1994 Jul;6(7):1027-36 [7524641.001]
  • [Cites] J Biol Chem. 1994 Nov 4;269(44):27224-30 [7525548.001]
  • [Cites] Int J Cancer. 1995 Jan 27;60(3):426-31 [7530236.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2166-70 [7857718.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):473-83 [7532131.001]
  • [Cites] J Immunol. 1995 Mar 1;154(5):2291-302 [7532664.001]
  • [Cites] Nat Struct Biol. 1994 Dec;1(12):898-907 [7773779.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1502-14 [7543524.001]
  • [Cites] Exp Cell Res. 1995 Aug;219(2):571-8 [7641809.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2086-90 [7545020.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4425-31 [7545541.001]
  • [Cites] Cancer Surv. 1995;24:67-79 [7553663.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):887-92 [8611401.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11067-75 [8626649.001]
  • [Cites] Blood. 1997 May 1;89(9):3385-95 [9129046.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):645-53 [9178821.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):763-70 [9422729.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):940-4 [9422753.001]
  • [Cites] Trends Biochem Sci. 1998 Jan;23(1):30-4 [9478133.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):848-53 [9485045.001]
  • (PMID = 17056038.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / Z01 ES023025-08; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibronectins; 0 / Integrin alpha5beta1; 0 / P-Selectin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS14907; NLM/ PMC1853301
  •  go-up   go-down


94. Martínez-Peñuela A, Rosario Mercado M, Aldave J, Martínez-Peñuela JM: [Primary adenocarcinoma of the seminal vesicles]. Arch Esp Urol; 2009 Oct;62(8):671-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the seminal vesicles].
  • [Transliterated title] Adenocarcinoma primario de vesículas seminales.
  • OBJECTIVES: To report one case of primary adenocarcinoma of the seminal vesicles.
  • Transrectal needle biopsy shows a primary adenocarcinoma of the seminal vesicles.
  • CONCLUSION: Primary adenocarcinoma of the seminal vesicles is an extremely uncommon neoplasm that is often difficult to diagnose as it has in specific morphology and can be confused with other primary adenocarcinomas from prostate, bladder or colon.
  • [MeSH-major] Adenocarcinoma. Genital Neoplasms, Male. Seminal Vesicles

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907060.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


95. Eriksen MT, Wibe A, Haffner J, Wiig JN, Norwegian Rectal Cancer Group: Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy. Dis Colon Rectum; 2007 Feb;50(2):156-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy.
  • METHODS: This was a national cohort study of 2,460 patients with pT3 rectal adenocarcinoma, undergoing major surgery without preoperative radiotherapy from November 1993 to December 2002.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17180256.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Guo J, Zhou AW, Fu YC, Verma UN, Tripathy D, Frenkel EP, Becerra CR: Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. Acta Pharmacol Sin; 2006 Oct;27(10):1375-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.
  • METHODS: HCT116 colon cancer cells were treated with docetaxel, flavopiridol, and 5-FU in several different administrative schedules in vitro, either sequentially or simultaneously.
  • RESULTS: The maximum cytotoxicity was found when human colon cancer HCT116 cells were treated with docetaxel for 1 h followed by flavopiridol for 24 h and 5-FU for another 24 h.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Colonic Neoplasms / pathology

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007746.001).
  • [ISSN] 1671-4083
  • [Journal-full-title] Acta pharmacologica Sinica
  • [ISO-abbreviation] Acta Pharmacol. Sin.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 0 / Taxoids; 15H5577CQD / docetaxel; 45AD6X575G / alvocidib; U3P01618RT / Fluorouracil
  •  go-up   go-down


97. Yeung EY, Sueyoshi T, Negishi M, Chang TK: Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos; 2008 Nov;36(11):2270-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine whether G. biloba extract induces hPXR target gene expression, cultured LS180 human colon adenocarcinoma cells were treated for 72 h with the extract. G. biloba extract at 200, 400, and 800 microg/ml increased CYP3A4 mRNA expression by 1.7-, 2.4-, and 2.5-fold, respectively.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Animals. Cell Line, Tumor. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. Dose-Response Relationship, Drug. Gene Expression Regulation, Neoplastic / drug effects. Gene Targeting. Humans. Mice. Plant Extracts / isolation & purification. Plant Extracts / pharmacology. Plant Leaves / physiology. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858673 for PMID:18725505 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2004 Aug;310(2):528-35 [15075359.001]
  • [Cites] Cell. 1998 Jan 9;92(1):73-82 [9489701.001]
  • [Cites] Mol Endocrinol. 2000 Jan;14(1):27-39 [10628745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7500-2 [10852961.001]
  • [Cites] Drug Metab Dispos. 2001 Nov;29(11):1499-504 [11602528.001]
  • [Cites] Mol Pharmacol. 2001 Dec;60(6):1399-406 [11723248.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 May;49(5):391-7 [11976833.001]
  • [Cites] Mol Endocrinol. 2002 May;16(5):977-86 [11981033.001]
  • [Cites] J Chromatogr A. 2002 Aug 16;967(1):21-55 [12219929.001]
  • [Cites] Clin Pharmacol Ther. 2002 Sep;72(3):276-87 [12235448.001]
  • [Cites] Life Sci. 2002 Apr 26;70(23):2783-92 [12269382.001]
  • [Cites] Drug Metab Dispos. 2003 Jan;31(1):7-10 [12485946.001]
  • [Cites] Jpn J Pharmacol. 2002 Dec;90(4):345-51 [12501011.001]
  • [Cites] J Clin Psychopharmacol. 2003 Dec;23(6):576-81 [14624188.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 11;318(4):1072-8 [15147983.001]
  • [Cites] Mol Pharmacol. 1996 Feb;49(2):311-8 [8632764.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49307-14 [15347657.001]
  • [Cites] Xenobiotica. 2005 Jan;35(1):69-83 [15788369.001]
  • [Cites] Drug Metab Dispos. 2006 Feb;34(2):234-42 [16258077.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Mar;316(3):1369-77 [16267138.001]
  • [Cites] Life Sci. 2006 Mar 27;78(18):2066-72 [16507312.001]
  • [Cites] Drug Metab Rev. 2006;38(1-2):51-73 [16684648.001]
  • [Cites] Drug Metab Rev. 2006;38(3):515-97 [16877263.001]
  • [Cites] J Clin Pharmacol. 2006 Nov;46(11):1290-8 [17050793.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Dec 1;217(2):225-33 [17045319.001]
  • [Cites] Mol Pharmacol. 2007 Jan;71(1):220-9 [17028159.001]
  • [Cites] Biochim Biophys Acta. 2007 Mar;1770(3):478-88 [17097810.001]
  • [Cites] J Biol Chem. 2007 Mar 30;282(13):9768-76 [17267396.001]
  • [Cites] J Pharm Pharmacol. 2007 Jun;59(6):871-7 [17637180.001]
  • [Cites] Pharmacogenomics. 2008 Jan;9(1):105-27 [18154452.001]
  • [Cites] Mol Pharm. 2008 Jan-Feb;5(1):35-41 [18159929.001]
  • [Cites] Curr Med Res Opin. 2008 Feb;24(2):591-9 [18205997.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2008 May;102(5):466-75 [18331390.001]
  • [Cites] Mol Pharmacol. 2008 May;73(5):1474-83 [18245269.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2008 Jun;102(6):515-26 [18331392.001]
  • [Cites] Drug Metab Dispos. 2008 Jun;36(6):1172-80 [18332086.001]
  • [Cites] J Agric Food Chem. 2008 Jul 9;56(13):5366-73 [18540626.001]
  • [Cites] Drug Metab Dispos. 2008 Aug;36(8):1538-45 [18474680.001]
  • [Cites] Drug Metab Lett. 2008 Jan;2(1):60-6 [19356072.001]
  • [Cites] Mol Pharmacol. 1999 Dec;56(6):1329-39 [10570062.001]
  • (PMID = 18725505.001).
  • [ISSN] 1521-009X
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Receptors, Steroid; 0 / pregnane X receptor
  • [Other-IDs] NLM/ NIHMS75380; NLM/ PMC2626634
  •  go-up   go-down


98. Kim CH, Kim MY, Moon JY, Hwang JW, Lee SY, Joo YM, Han SI, Park HG, Kang HS: Implication of NAG-1 in synergistic induction of apoptosis by combined treatment of sodium salicylate and PI3K/MEK1/2 inhibitors in A549 human lung adenocarcinoma cells. Biochem Pharmacol; 2008 May 1;75(9):1751-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implication of NAG-1 in synergistic induction of apoptosis by combined treatment of sodium salicylate and PI3K/MEK1/2 inhibitors in A549 human lung adenocarcinoma cells.
  • Aspirin is used as chemopreventive agents in a variety of human cancer cells including those of colon, lung, breast, and leukemia.
  • Furthermore, simultaneous inhibition of the Akt/PKB and ERK1/2 signal cascades could lower the dose of NaSal to induce apoptosis to 2mM in A549 lung cancer cells.
  • Collectively, our findings indicate that inhibition of the pro-survival Akt/PKB and ERK1/2 signaling may increase the chemopreventive effects of NaSal and combined treatment of two natural compounds (NaSal and genistein) results in a highly synergistic induction of apoptosis, thereby increasing the chemopreventive effects of NaSal against cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358453.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Elafin; 0 / Enzyme Inhibitors; 0 / GDF15 protein, human; 0 / Growth Differentiation Factor 15; 0 / PI3 protein, human; 0 / RNA, Small Interfering; EC 2.7.1.- / MAP2K1 protein, human; EC 2.7.1.- / MAP2K2 protein, human; EC 2.7.12.2 / MAP Kinase Kinase 1; EC 2.7.12.2 / MAP Kinase Kinase 2; WIQ1H85SYP / Sodium Salicylate
  •  go-up   go-down


99. Kim HW, Cai QY, Jun HY, Chon KS, Park SH, Byun SJ, Lee MS, Oh JM, Kim HS, Yoon KH: Micro-CT imaging with a hepatocyte-selective contrast agent for detecting liver metastasis in living mice. Acad Radiol; 2008 Oct;15(10):1282-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two mice each were randomly selected on days 3, 5, 7, 10, and 13 after CT26 colon adenocarcinoma cells were injected into the portal vein; micro-CT imaging was performed at 10 minutes and 4 hours after intravenous administration of a hepatocyte-selective contrast agent at a dose of 0.4 mL/mouse.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / secondary. Contrast Media. Hepatocytes / radiography. Liver Neoplasms / radiography. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790400.001).
  • [ISSN] 1878-4046
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


100. Saif MW, Siddiqui IA, Sohail MA: Management of ascites due to gastrointestinal malignancy. Ann Saudi Med; 2009 Sep-Oct;29(5):369-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cancers associated with ascites are adenocarcinomas of the ovary, breast, colon, stomach and pancreas.
  • There are many potential causes of ascites in cancer patients, including peritoneal carcinomatosis, malignant obstruction of draining lymphatics, portal vein thrombosis, elevated portal venous pressure from cirrhosis, congestive heart failure, constrictive pericarditis, nephrotic syndrome and peritoneal infections.
  • Median survival after diagnosis of malignant ascites is in the range of 1 to 4 months; survival is apt to be longer for ovarian and breast cancers if systemic anti-cancer treatments are available.
  • [MeSH-major] Adenocarcinoma / complications. Ascites / therapy. Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ital J Gastroenterol Hepatol. 1999 Oct;31(7):626-34 [10604107.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1207-14 [9816289.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):445-54 [10675474.001]
  • [Cites] Palliat Med. 2000 Jan;14(1):62-4 [10717726.001]
  • [Cites] Arch Intern Med. 2001 Dec 10-24;161(22):2733-7 [11732940.001]
  • [Cites] Palliat Med. 2002 May;16(3):213-8 [12046997.001]
  • [Cites] Hepatology. 2003 Jul;38(1):258-66 [12830009.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1646-54 [15084697.001]
  • [Cites] Surgery. 1974 Feb;75(2):299-304 [4590763.001]
  • [Cites] Arch Intern Med. 1979 Feb;139(2):235 [434979.001]
  • [Cites] Am J Clin Oncol. 1982 Apr;5(2):167-72 [6178284.001]
  • [Cites] Br J Surg. 1982 Aug;69(8):441-2 [7049306.001]
  • [Cites] J Surg Oncol. 1982 Aug;20(4):238-42 [6180252.001]
  • [Cites] Br J Surg. 1983 Aug;70(8):478-81 [6871638.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Mar 10;288(6419):749-51 [6423061.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2226-30 [6207907.001]
  • [Cites] Cancer. 1985 May 1;55(9):1973-8 [3978577.001]
  • [Cites] Hepatology. 1985 May-Jun;5(3):403-7 [3888808.001]
  • [Cites] Cancer Treat Rev. 1985 Dec;12 Suppl B:23-32 [3833327.001]
  • [Cites] Ann Surg. 1986 Jun;203(6):644-51 [3718029.001]
  • [Cites] Hepatology. 1988 Sep-Oct;8(5):1104-9 [3417231.001]
  • [Cites] Adv Intern Med. 1990;35:365-73 [2405598.001]
  • [Cites] Ann Intern Med. 1990 Jun 15;112(12):889-91 [2187389.001]
  • [Cites] Eur J Cancer. 1991;27(2):121-5 [1827272.001]
  • [Cites] J Gastroenterol Hepatol. 1992 Mar-Apr;7(2):161-4 [1571498.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1302-6 [1397889.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):102-9 [1427388.001]
  • [Cites] Cancer. 1993 Mar 15;71(6):2027-30 [7680276.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):337-42 [8277955.001]
  • [Cites] Am J Hosp Pharm. 1994 May 1;51(9):1184-92 [8042637.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):378-81 [7531600.001]
  • [Cites] Hepatology. 1996 Jan;23(1):164-76 [8550036.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2201-6 [8572625.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):6-14 [8653366.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):237-9 [8654603.001]
  • [Cites] Medsurg Nurs. 1995 Dec;4(6):468-71 [8696395.001]
  • [Cites] N Z Med J. 1997 Feb 14;110(1037):33-5 [9066565.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1899-902 [9717817.001]
  • [Cites] J Pain Symptom Manage. 1998 Aug;16(2):96-101 [9737100.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):381-5 [9887235.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):300-8 [16240400.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):589-97 [16434188.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):709-13 [16739342.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):908-13 [17140897.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2348-57 [17505860.001]
  • [Cites] J Nippon Med Sch. 2007 Oct;74(5):355-8 [17965529.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Dec;22(12):2161-6 [18031375.001]
  • [Cites] QJM. 2008 Feb;101(2):71-85 [18184668.001]
  • [Cites] Palliat Med. 1999 Sep;13(5):429-30 [10659116.001]
  • (PMID = 19700895.001).
  • [ISSN] 0975-4466
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 55
  • [Other-IDs] NLM/ PMC3290049
  •  go-up   go-down






Advertisement